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The occlusion of peripheral arteries is a common affliction that severely reduces quality of 
life. Peripheral arterial disease (PAD) often leads to ischemia in the distal limb, thus 
requiring revascularization. Often, replacement or bypass of small diameter arteries (with 
internal diameter 6 mm) is performed to provide nutritive blood flow to the affected limb. 
Presently available synthetic small diameter vascular grafts tremendously fail because of 
high thrombogenicity and low patency. Topography and attachment cues on various inert 
biomaterials are known to improve adhesion, proliferation and migration of endothelial cells 
in vitro. It is hypothesized that topography or attachment cues will aid endothelialization of 
synthetic grafts, thus improving functionality and long-term patency. Meanwhile, sustained 
delivery of angiogenic factors from small diameter vascular graft may be used to stimulate 
endothelial cells to migrate, proliferate and form new blood vessels for revascularization. 
We postulated that controlled spatiotemporal release of angiogenic factor from a small 
diameter vascular graft may aid revascularization in PAD patients. Poly(vinyl alcohol) (PVA) 
is a biocompatible, non-antigenic, non-immunogenic, water-soluble polymer. In this study, 
we modified PVA hydrogel with topography, attachment factor and angiogenic factor for its 
use as a small diameter vascular graft. We showed the novel incorporation into planar and 
tubular PVA scaffolds of topography and attachment factors, both of which improved 
endothelial cell viability, proliferation and function. Polyelectrolyte fibers were also 
incorporated into PVA small diameter vascular grafts, forming a composite scaffold that 
allows near-linear release of angiogenic factor. Finally, we demonstrated the feasibility and 
short-term patency of PVA small diameter vascular graft in an animal model of PAD. PVA 
vascular grafts, with submillimeter dimension and mechanical properties matching that of 
the native artery, exhibited endothelial cells on its luminal surface after two-week 
implantation. Our study suggests that PVA has excellent potential as an ideal vascular graft 
due to its wide possibility for modification and resultant biological functionality, excellent 
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1.1 Small diameter vascular graft for peripheral arterial disease treatment 
Peripheral arterial disease (PAD) is a collection of chronic diseases characterized by the 
occlusion of arteries in the extremities, mostly commonly occurring in the lower legs. This 
disease affects 27 million people in Europe and the United States alone [1-3], with an 
incidence of 3-10% that increases to 15-20% at ages 70 years old and above [4,5]. 
Unlike other occlusive arterial diseases, PAD in itself is not fatal albeit it causes a large 
decrease in functional capacity and overall quality of life. At an early stage of PAD, 
patients most commonly experience claudication pain during ambulation when 
performing day-to-day activities. At a later stage of PAD, claudication pain is present 
even at rest, representing a severe lack of blood supply to the lower extremities. In the 
most extreme case of critical limb ischemia, blood supply is insufficient at rest, resulting 
in foot ulceration, gangrene, or even amputation and permanent debilitation. In this case, 
atherosclerotic occlusions extend throughout the length or lodge at multiple locations in 
the artery, making surgical revascularization imperative for treatment.   
 
The replacement or bypass of a peripheral artery usually involves the harvest of an 
autologous blood vessel. However, the systemic nature of atherosclerosis means that 
these autologous vessels are not sufficiently healthy for use in peripheral bypass. In 
addition, a higher mortality risk from the additional surgery precludes the elderly or 
patients with comorbidities from this procedure. Alternatively, synthetic vascular grafts 
are available for those who do not have autologous grafts. Synthetic vascular grafts have 
long been proven to be effective and patent in the long-term for large arteries, yet fail 
tremendously at diameters less than 6 mm. The lack of endothelialization, rapid 
thrombosis rate and incidence of intimal hyperplasia have all contributed to disappointing 
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patency rates of small diameter grafts in clinical applications. Therefore, there is a 
clinical need for effective small diameter vascular grafts made from synthetic materials. 
 
Poly(vinyl alcohol) (PVA) is a widely used synthetic and biocompatible polymer for 
applications such as contact lens and blood-contacting tubes. PVA has been previously 
explored as a small diameter vascular graft in a rat abdominal aorta model. Using a 
novel chemical cross-linking method, PVA small diameter vascular graft (internal 
diameter (ID) of 2 mm) with desirable mechanical properties was fabricated [6]. They 
were observed to be patent for 1 week, albeit without any endothelial cells in the lumen. 
The bioactivity, and consequent endothelialization, of PVA small diameter vascular grafts 
must be improved for its long-term application. 
 
Topographical cues that mimic the biophysical environment of cells in situ have been 
shown to control cellular behavior in vitro. For example, topographical cues have been 
shown to improve endothelial cell attachment and proliferation [7,8]. In addition, 
attachment factors grafted on surfaces have been widely used for improving cell 
attachment on inert biomaterials [9-11]. Topographical cues and attachment factors, 
singularly or in combination, may direct endothelial cell behavior to stimulate in situ 
endothelialization. Furthermore, vascular grafts with controlled release of biomolecules 
that promote growth of new blood vessels may augment revascularization and treatment 
of an ischemic limb [12]. 
1.2 Hypothesis 
In this study, it is hypothesized that the incorporation of topographical cues and 
biochemical cues such as attachment factors or controlled release of growth factors will 
improve biological functionality, endothelialization and patency of PVA small diameter 
vascular grafts, ultimately leading to treatment of PAD. 
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1.3 Aims of the study 
The objective of the study is to improve the patency of small diameter vascular grafts 
through incorporation of topographical and biochemical cues. The synthetic polymer PVA 
was investigated as a potential material for biofunctionalization and fabrication of small 
diameter vascular graft. We aim to achieve the following goals:  
 
1. To modify PVA with various topographical cues and attachment factors to improve 
endothelial cell adhesion, proliferation and function on PVA scaffolds. 
 
2. To incorporate a vehicle for the sustained and controlled release of bioactive growth 
factor from PVA small diameter vascular grafts. 
 
3. To examine the efficacy and patency of unmodified PVA small diameter vascular 













2.1 Peripheral arterial disease 
2.1.1 Pathophysiology of PAD 
Peripheral arterial disease (PAD) is one manifestation of a systemic atherosclerotic 
disease that is characterized by the occlusion of the blood vessels of the extremities 
[3,5]. It originates from lipid imbalance, disturbed endothelium and a chronic 
inflammatory process [3,13,14]. In atherogenesis, a damaged vessel endothelium leads 
to accumulation and oxidation of low-density lipoproteins in the subendothelial layer. The 
oxidized lipids, in turn, will induce chemokine release that will start a positive feedback 
loop of immune cell infiltration and further lipoprotein oxidation to create a plaque in the 
vessel wall. When it ruptures, a plaque can expose underlying components of the vessel 
wall that can activate platelets and initiate the blood-clotting cascade [15]. After initial 
plaque rupture and thrombus formation, lesions may rapidly progress to become 
occlusive wall thrombus.  
2.1.2 Current treatment for PAD 
After accurate assessment of PAD severity, a two-pronged interventional program for 
treatment will be implemented [3]. First and foremost, people at risk or at an early stage 
of PAD undergo lifestyle changes and take long-term medication, including aspirin, 
clopidogrel (anti-platelets) and statins (anti-cholesterolemic). Both programs are intended 
to treat symptoms, prevent progression of the disease, reduce the systemic 
atherosclerotic state and prevent cardiovascular mortality [16]. In addition, experimental 
treatment using angiogenic factors are currently being explored to supplement or 
supplant existing treatments. For those with more severe arterial occlusions, 
interventional surgical treatment is given.  
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2.1.2.1 Therapeutic angiogenesis for PAD 
Vascular regeneration is a valid and significant therapeutic strategy for treatment of PAD. 
It entails the restoration of normal vascular function, as well as formation of new 
vasculature [17]. By restoring normal blood flow, ischemia, acute thrombosis and 
amputation of the lower limb can be prevented. The intricate and tightly controlled 
process of angiogenesis, which is the formation of new blood vessels from existing ones, 
is primarily responsible for vascular regeneration [18]. Maturation of these vessels can 
occur with continuous stimulation by angiogenic factors, leading to recruitment of 
pericytes and smooth muscle cells. Eventually, small capillaries will mature to form small 
arterioles that will have a higher capacity to provide nutritive flow to ischemic tissues, 
thereby restoring its functionality [19]. Several different approaches have been used to 
achieve therapeutic angiogenesis: DNA, stem cells, small-molecule drugs, and 
recombinant growth factor.  
 
One of the more established methods for inducing angiogenesis is the use of 
recombinant growth factors. For instance, vascular endothelial growth factor (VEGF), the 
most potent mitogenic, angiogenic and arteriogenic factor for endothelial cells, has been 
widely used for augmentation of ischemia in animal models [20,21]. Physiologically, 
VEGF is overexpressed in areas that experience low oxygen tension as a means to 
improve local oxygen supply thru the activation of hypoxia-sensitive transcription factors. 
Thus far, the use of recombinant VEGF for therapy has yet to provide convincing efficacy 
in clinical trials [22,23]. It has been shown that the sustained delivery of growth factor 
and maintenance of local concentration is necessary for activating endothelial and 
hematopoietic stem cell proliferation and maintenance of stable neovessels [24,25]. 
Withdrawal of a consistent VEGF signal within two weeks of onset will regress collaterals 
and contract blood flow. Therefore, the success of growth factors for therapeutic 
angiogenesis requires a system for its controlled and sustained delivery. 
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2.1.2.2 Surgical intervention for PAD 
For patients with debilitating claudication pain and critical limb ischemia, it is necessary 
to be treated thru surgical interventional programs. Endovascular methods such as 
stenting and angioplasty are robust for treating chronic total occlusion of the superficial 
femoral, popliteal and tibial arteries, showing up to 91% limb salvage rates for patients 
with critical limb ischemia [26]. Multiple follow-up reinterventions may be necessary for 
these patients, but it is a good option for those with a high operative mortality risk [26]. 
Since PAD patients have a systemic atherosclerotic problem though, it is common to 
have cases where occlusion occurs throughout the entire length of the artery, and 
perhaps even involving multiple arteries [5]. In this case, surgical revascularization 
procedures must be used to resuscitate the limb [16]. 
 
Arterial bypass or replacement commonly uses autologous saphenous vein, internal 
mammary artery or radial artery grafts. Autologous grafts remain the gold standard for 
both above-the-knee and below-the-knee bypass surgeries because of its 
biofunctionality and excellent long-term patency [27-29]. However, when these vessels 
are diseased, insufficient in length or is accompanied by an increased morbidity risk, 
alternatives must be used. Vascular grafts from other natural materials have been shown 
to demonstrate short-term patency despite lack of mechanical integrity. In contrast, 
vascular grafts made from synthetic materials were shown to have adequate 
performance for above-the-knee bypass [1,4]. In contrast, revascularization of more 
distal vessels (femoral, popliteal or tibial arteries) have more dismal outcomes with 
patency rates at 54% for autologous saphenous vein, 45% for expanded 
polytetrafluoroethylene (ePTFE) grafts, while all poly(ethylene terephthalate) (Dacron) 
grafts were found to occlude at 10 months [30]. As such, there is still a need for a small 
diameter vascular graft to treat PAD. 
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2.2. Current Developments in Small Diameter Vascular Grafts  
2.2.1 Biomaterials used for small diameter vascular grafts 
The use of naturally derived materials, such as extracellular matrix (ECM) proteins or 
polysaccharides, for small diameter vascular grafts is promising because of its inherent 
bioactivity. A collagen gel graft (Omniflow, Bionova, Australia) reported 1-year patency 
rate of 60% and 5-year patency rate of 40% in below-the-knee bypass. Additionally, a 
cross-linked hydrogel of polysaccharides was molded into 2 mm ID vascular grafts and 
reinforced externally by a nylon mesh [31]. The polysaccharide grafts remained patent 
up to 8 weeks with neointimal formation after implantation in a rat infrarenal aorta model. 
Similarly, a decellularized smooth muscle cell scaffold strengthened externally with a 
cylindrical poly(glycolic acid) scaffold remained patent for 6 months in a baboon model 
[32,33]. In a recent study, collagen fiber networks with polymeric elastin-mimic were 
used to create vascular grafts [34]. However, an early inflammatory response was 
detected at 2 weeks after implantation in a rat abdominal aorta. While naturally derived 
materials have excellent bioactivity and capacity for tissue regeneration, its utility in 
vascular tissue engineering is compromised by its lack of durability and elasticity, 
potential antigenicity and pathogen transmission in vivo. Moreover, lack of an industrial-
scale production method for ECM proteins imply a high cost for the fabrication of 
vascular grafts. In addition, disparities in processing and production of natural materials 
may also translate into variations in clinical results.  
 
The use of biocompatible synthetic materials may be more advantageous for tissue 
engineering applications because of its processability and flexibility for functionalization 
or modification. Specific definition of chemical, physical and mechanical properties of 
synthetic biomaterials are more flexible compared to that of natural materials. Synthetic 
materials such as ePTFE, Dacron and polyurethane (PU) are most commonly used as 
an alternative for vascular replacement. Though these materials perform well for large 
diameter vessels, they are less than optimal in small diameter (less than 6 mm) settings. 
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The increased occurrence of intimal hyperplasia, surface thrombogenicity, lack of 
endothelialization and compliance mismatch with the native vessel all contribute to 
disappointing patency rates for diameters less than 6 mm [35,36]. A main issue with 
ePTFE and Dacron is its lack of mechanical compliance, leading to thrombosis 5 years 
after implantation. Meanwhile, elastomeric PU has high elasticity, tensile strength, and 
resistance to fatigue [37]. However, early polyether and polyester-based PU grafts were 
compromised by its rapid biodegradation in vivo [38]. Polycarbonate-based PU has 
improved biostability and rapid endothelialization, but lacking any significant benefit in 
early clinical studies for below-the-knee replacements [39].  
 
Other synthetic polymers have also been explored. For example, poly(caprolactone) 
(PCL) vascular grafts (2.2 mm ID) remained patent at 4 weeks in rabbit carotid arteries 
[9] and up until 18 months in a rat abdominal aorta model [40] but with calcific deposits in 
the long term, which may undermine its clinical application. Commercially available 
synthetic small diameter vascular grafts, though increasingly improving in performance, 
still fail to produce impressive long-term patency rates indicative of permanent 
rehabilitation. There is currently a great need for synthetic small diameter vascular grafts 
that have hematological and biological compatibility, mechanical and biofunctional 
properties to provide the appropriate environment for endothelialization [36,41].  
 
2.2.2 Poly(vinyl alcohol) 
Poly(vinyl alcohol) (PVA) is a popular synthetic polymer for a myriad of biomedical 
applications. It is non-toxic, non-immunogenic, non-carcinogenic and highly 
biocompatible [42]. The ease of fabrication and availability of PVA also makes it an 
attractive polymer of choice. PVA has found a variety of uses in medicine and therapy as 
a cross-linked hydrogel, allowing it to imbibe water while maintaining its structural 
integrity in an aqueous environment (Table 1). Furthermore, the elastic mechanical 
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property and transparency of PVA make it an attractive choice for various implantation 
applications. Several methods for cross-linking PVA are known, yielding hydrogel with 
different properties. In the 1960s, a formaldehyde-cross-linked PVA sponge (marketed 
as “Ivalon”) gained some success as a versatile material for various medical 
applications. For example, Ivalon was tested as a vascular graft for arterial replacement, 
albeit with conflicting results. Short-term animal studies found full patency of Ivalon grafts 
in both abdominal and thoracic aorta of mongrel dogs [43]. Meanwhile, in clinical 
application, Ivalon was shown to have a maximum patency of only 6 months, after which 
complications made it impossible to follow-up. Moreover, the loss of elasticity and the 
increase in the brittleness were notable in the Ivalon grafts [44]. 
 
PVA has also been irradiated at a temperature above the glass transition by both 
electron beam [45,46] and gamma irradiation [47] for cross-linking via free radical 
formation. The elasticity, crystallinity and transparency of the PVA films fabricated with 
electron beam irradiation demonstrated permeability to oxygen, making it attractive for 
contact lens application. Though the PVA hydrogel created using electron beam 
irradiation lacked tensile strength, those cross-linked with gamma irradiation showed 
maximum tensile strength of 11 MPa. This demonstrated that the control of irradiation 
dose could be used to tune PVA mechanical properties. Afterwards, a physical cross-
linking method involving very controlled freeze-thawing processes was shown to have 
desirable mechanical properties for use in heart valve stent [48] and drug delivery 
[49,50]. Thus, different cross-linking methods produced PVA hydrogel with a range of 
mechanical properties, each one tailored to produce a scaffold for a specific tissue 
application. Moreover, it is apparent that control of the cross-linking of the PVA polymer 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































An alternative approach to create PVA hydrogel is to use a cross-linking method that 
does not involve any toxic compounds, organic chemicals or heat. Sodium 
trimetaphosphate (STMP), commonly found in cosmetic formulations and bath oils, do 
not have known genotoxic, carcinogenic or teratogenic effects [51]. In 2008, Chaouat et 
al. described a preliminary study on cross-linking of PVA with STMP for vascular tissue 
engineering [6]. The simple cross-linking process of PVA involved activation of hydroxyl 
groups with sodium hydroxide (NaOH) and addition of an aqueous solution of STMP at 
ambient conditions. This activated solution was then used to create PVA tubular 
scaffolds (2 mm ID) that had mechanical properties approximating that of the rat 
abdominal aorta. Subsequent implantation of PVA small diameter grafts in a rat 
abdominal aorta model demonstrated patency up until 7 days of implantation. However, 
the lack of bioactivity and endothelialization of the PVA vascular grafts need to be 
addressed to improve long-term performance after implantation. 
 2.3 Requirements for small diameter vascular grafts 
Though ePTFE, Dacron and PU perform well for vascular grafts larger than 6 mm due to 
the turbulent and high shear stress of blood flow that disperse various clotting factors 
[52], they fail for small diameter applications. Various factors have been shown to affect 
patency of small diameter vascular grafts.  
2.3.1 Blood compatibility and surface thrombogenicity  
Biocompatibility of small diameter vascular grafts must be defined not only by its lack of 
elicited immune response, but also by its blood compatibility. Two pathways for blood 
coagulation, the intrinsic (surface-mediated) and extrinsic (tissue factor-mediated), 
converge to activate thrombin and form a fibrin clot. The intrinsic pathway is activated 
when Factor XII, high molecular weight kininogen and prekallikrein come into contact 
with a positively charged surface [53]. This triggers a cascade of enzymatic protein 
cleavage and thrombus formation. At the anastomosis site, injured endothelial cells will 
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express tissue factor (TF) that will activate the extrinsic pathway of blood coagulation. 
Factor VIIa from the blood will then bind to TF on cell membranes, forming an active 
complex that can trigger the coagulation cascade and form a blood clot. Inflammatory 
cells may also express TF on the cell surface upon contact with a biomaterial surface. 
The two pathways of blood coagulation are initiated by different stimuli, though converge 
by activating both Factor IX and Factor X [52]. 
 
Platelets also play a role in thrombus formation. Blood coagulation proteins or collagen 
from damaged vessels may activate platelets, which in turn will amplify platelet activation 
or thrombus formation. Platelets may also directly adhere to material surfaces using 
GPIIb/IIIa integrin receptor, leading to the release of microparticles and other platelet 
cytokines that promote further activation. 
 
The complement system, on the other hand, has been widely disregarded in in vitro 
biocompatibility studies of various materials. In fact, the complement response is 
considered to be responsible for various complications associated with use of 
cardiovascular bypass devices. The complement system is made up of plasma proteins 
that act to phagocytose intruding materials or induce inflammation. Activation of the 
complement system as triggered by biomaterials surfaces occurs through the alternative 
pathway. The activation of the complement pathway relies solely on the chemical 
composition of the biomaterial and its affinity for the C3b complement protein. A 
fundamental question of the acceptable level of complement activation induced by 
biomaterials is still unanswered. Nevertheless, this should be taken into consideration 
when designing blood-contacting devices made from novel biomaterials. 
2.3.2 Bulk mechanical properties and compliance matching 
The mechanical properties of arteries are complex and vascular grafts must imitate these 
properties to ensure patency. Most important of these characteristics is compliance, or 
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the dependence of the mechanical property on the hydrostatic pressure within the graft. 
Differences in compliance across an anastomosis site were shown to induce 
hemodynamic changes, which may either increase or decrease shear stress [32]. 
Reduction of wall shear stress leads to a compensatory increase in proliferation of 
smooth muscle cells or intimal hyperplasia to reduce luminal diameter, thus returning 
shear stress back to physiological levels, according to Poiseuille’s law [40]. On the other 
hand, increase in wall shear stress may cause injury to endothelial cells, thus also 
leading to intimal hyperplasia [40]. Low oscillations of wall shear stress, due to the lack 
of pulsatile propagation through a non-compliant vascular graft, may also cause 
thrombogenicity by increasing serum protein and blood component interaction with the 
synthetic surface [54]. A study by Stewart et al. [55] on compliance mismatched grafts 
under reduced pulsatile flow, similar to that of peripheral arteries, revealed an area of 
stagnation that traps particles within an area of insufficient pressure. 
 
Though compliance matching theoretically should improve implant patency, the 
phenomenon of peri-anastomotic hypercompliance after graft implantation complicates in 
vivo outcomes. At 2 to 3 mm away from both proximal and distal anastomotic lines, a 
peri-anastomotic hypercompliance zone is created, where compliance is changed from  
bulk, in vitro compliance to somewhere in between that of the implant and the native 
artery. Meanwhile, a local minimum compliance is achieved exactly at the anastomotic 
line [40]. 
 
Matching of conduit caliber is also important for maintaining flow velocity of blood. Blood 
vessels taper naturally as they run from the proximal to the distal side. Using synthetic 
grafts that are too small results in extremely high flow velocities at the distal anastomosis 
site, which may lead to intimal hyperplasia [40]. In addition, mismatch in internal 
diameters cause increased impedance that alters shear stress as well [32]. On the other 
hand, grafts that are extremely big will cause a drop in blood velocity that results in flow 
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stasis and reduced shear stress, also resulting in intimal hyperplasia. Specifically, a 
vascular graft with just 6% diameter mismatch may cause a measurable decrease in wall 
shear stress at the distal anastomosis site [56]. Therefore, matching of both conduit 
caliber and compliance are necessary to promote patency of small diameter vascular 
grafts. 
2.3.3 Endothelialization 
Endothelial cells are the natural lining of blood vessels that act as an intermediary 
between the blood and the artery. Any disruption in blood chemistry, hemodynamics, 
mechanical (oscillatory, pulsatile or viscous) stress or integrity of the intimal cell 
monolayer will cause endothelial cells to respond appropriately. Endothelial cells also 
react against or contain inflammatory, thrombogenic and fibrinolytic events. For this 
reason, the endothelium is said to be a crucial, active component for biochemical and 
hemodynamic regulation of the circulatory system [57]. The importance of 
endothelialization of implanted vascular grafts therefore becomes manifest in the 
prevention of thrombosis, hyperplasia and immune reactions against a foreign material.  
A confluent monolayer of endothelial cells on vascular grafts is imperative to the long-
term success of a vascular graft.  
 
Numerous studies have demonstrated the feasibility of seeding either endothelial cells or 
endothelial progenitor cells (EPC), which are precursors of endothelial cells circulating in 
the blood [58], onto vascular grafts prior to implantation. For example, Zhou et al. [59] 
showed promising results in the seeding of EPCs on decellularized canine carotid 
arteries. At 3 months, patency rate for 4 to 5 cm graft lengths was 95% in a canine 
carotid artery model. However, this technique will require a considerable amount of time 
and money for manufacture and may not be easily available off the shelf. Autologous 
endothelial cells or EPC requires harvest and in vitro expansion before seeding to 
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produce customized vascular grafts. Storage and delivery of vascular grafts may also 
limit its commercialization and off-the-shelf usage.  
 
Alternatively, endothelialization of vascular grafts may be done through stimulation of 
endothelial cell migration, attachment and proliferation after implantation. This technique 
avoids tedious in vitro cell expansion and allows large-scale, commercial production of 
vascular grafts. However, spontaneous in situ endothelialization occurs at a very slow 
rate naturally and may vary from patient to patient. Therefore, it is necessary to introduce 
various moieties and modifications on inert, synthetic biomaterials that will stimulate 
endothelial cell or EPC migration, capture and proliferation. Various modifications are 
available to specifically target endothelial cells for the endothelialization of a small 
diameter vascular graft. 
2.4 Surface functionalization of small diameter vascular grafts to improve in situ 
endothelialization 
 
Both biochemical and biophysical factors are available to control endothelial cell 
behavior. It is hypothesized that through the action of these factors, one can enhance the 
rate and extent of in situ spontaneous endothelialization of vascular grafts.  
2.4.1 Functionalization with attachment factors 
Surfaces may be functionalized with proteins or peptides that can be used to control cell-
material interactions and direct cell behavior [60]. Popular protein choices for 
biofunctionalizing inert materials are ECM attachment proteins such as fibronectin [61], 
vitronectin [62] and laminin [63]. Thrombogenicity of these proteins, however, may not be 
feasible for its application in vascular tissue engineering. An alternate approach utilizes 
the RGDS (Arginine-Glycine-Aspartic Acid-Serine) or REDV (Arginine-Glutamic Acid-
Aspartic Acid-Valine) moiety in these ECM proteins that bind cell surface integrins for 
adhesion. In contrast to its full-length precursors, RGDS and REDV peptides are known 
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to increase cell attachment without the concomitant activation of GPIIb/IIIa platelet 
integrin receptors [64,65]. In fact, RGD peptides are prevalent in cardiovascular material 
modification because of its positive effect on endothelial cell and EPC capture [9,66-68] 
and resistance to platelet activation. Possibly the first instance of RGD used as a surface 
coating for improving vascular endothelial cell attachment was given by Massia et al. [69] 
wherein RGD was attached to Dacron and ePTFE to improve endothelial cell 
attachment. Four hours after seeding, endothelial cells covered RGD-coated substrates 
extensively, as compared to uncoated substrates. Morphologically, endothelial cells on 
RGD substrates showed more spreading and less clumping, with an organized actin 
cytoskeleton. Zheng et al. also modified PCL vascular grafts (ID 2.2 mm) to contain RGD 
peptides at the luminal surface [9]. PCL-RGD grafts induced significantly less platelet 
activation than PCL grafts alone. Significantly, implantation of the vascular graft in a rat 
abdominal aorta model after only 2 weeks demonstrated 30% endothelialization. After 4 
weeks of implantation, half of the graft was endothelialized in contrast to PCL grafts 
alone that showed approximately 10% endothelialization. As evidenced by the extent of 
endothelialization, all 5 PCL-RGD grafts were patent after 4 weeks while only 3 out of 5 
were patent for plain PCL.  
 
A cyclic form of RGD, which involves a disulfide bond between the first and last amino 
acids, was shown to have higher potency than linear RGD moieties in vitro to inhibit the 
platelet integrin GPIIb/IIIa [70,71]. This results in better retardation of the platelet 
response compared to linear RGD derivatives. Furthermore, cyclic RGD (cRGD) 
preferentially improves vascular endothelial cell adhesion better than linear RGD 
peptides by binding to αvß3 integrin receptor. For small diameter vascular grafts, 
McMillan et al. passively adsorbed gold-coated PU scaffolds with cRGD, CRGD and 
CREDV peptides  [62]. A significant extent of the cRGD-coated PU substrates had 
higher endothelialization. Moreover, it should be noted that despite the higher amount of 
serum protein adsorbed on cRGD-coated substrates, there was a lack of adsorption of 
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coagulation factors compared to CREDV-coated surfaces. RGD peptides therefore, are 
excellent for biofunctionalizing surfaces that are not amenable for vascular endothelial 
cell attachment.!
2.4.2 Functionalization with heparin 
One of the most common approaches for modifying blood-contacting materials is the 
addition of heparin. Heparin is a natural polysaccharide with anticoagulant properties 
made up of sulfated glycosaminoglycans. The inhibition of blood clotting involves the 
ability of heparin to recruit antithrombin III for deactivating thrombin and Factor Xa 
function.  
 
Though freeform soluble heparin is mainly used to inhibit blood coagulation and 
sequester various growth factors such as VEGF [72], the function of surface-immobilized 
heparin varies [53]. Surface bound heparin still retains its activity of preventing blood 
clotting, thereby ensuring that acute thrombogenic and inflammatory response to a 
foreign surface is inhibited, allowing endothelialization to occur. For example, ePTFE 
surfaces modified with heparin have promising below-the-knee bypass results: 75% of 
femoropopliteal bypass and 60% of infrapopliteal bypass remained patent in 5 years, 
possibly due to the lack of blood clots. Significantly, surface-bound heparin may also 
directly affect endothelialization by increasing adsorption of fibronectin from serum [53]. 
For example, Ishii et al. [73,74] observed endothelialization of the anastomotic- and mid-
sites of the PU graft with heparin (ID 3.6 mm, length 24 mm) as early as 3 months. In 
contrast, endothelialization of non-heparinized PU grafts were only visible at 6 months 
post-implantation. Another study using heparin-PU grafts (ID 1.2 mm) also showed faster 
endothelialization and a higher patency rate (100%) after 2 months of implantation, 
compared to unmodified PU [75]. Therefore, the incorporation of heparin may improve 
both endothelialization and hemocompatibility of small diameter vascular grafts. 
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2.4.3 Functionalization with topographical cues  
It is becoming more apparent that the effect of physical cues and forces is as important 
as well-known biochemical cues in directing cell behavior. The ECM hydrogel, instead of 
simply providing an inert structural support for cell attachment, actually provides the 
complex combination of biochemical and biophysical cues to direct cell behavior. The 
ECM is a composite of proteins and sugars, with biochemical and physical (mechanical 
and topographical) properties that combine to maintain a specific cell phenotype. The 
ECM acts as a reservoir for the regulated release of growth factors and enzymes that are 
necessary for directing cell growth and tissue remodeling. Additionally, various 
components of the ECM can provide topographical cues for the attachment and 
organization of cells. For instance, the ECM protein collagen provides an amino acid 
sequence for attachment of integrin molecules on the cell surface while providing fibrillar 
structures that cells recognize, bind and respond to [76-78]. 
 
Topographical cues may aid in the in situ endothelialization of vascular grafts through the 
promotion of either trans-anastomotic migration (migration of endothelial cells from the 
native vessel to the vascular graft across the anastomotic site) and subsequent 
proliferation of endothelial cells or capture of circulating endothelial cells and EPC. 
Uttayarat et al. showed the increased migration and retention of endothelial cells on 
microgrooves (with 1 µm depth) under shear stresses of physiological and pathological 
magnitude [79]. In addition, Liliensiek et al. [8] used different topographical cues to show 
increased endothelial cell proliferation on nano-meter sized ridges and holes. They also 
observed increased migration rate of endothelial cells in micro-meter sized ridges with 
heights of 1.2, 1.6, 2 and 4 µm, demonstrating the myriad phenotypic or functional 
effects that various topographical cues can induce in endothelial cells. 
 
Aside from its effect on endothelial cell migration and proliferation, a recent study has 
shown that microsized gratings maintain its physiological phenotype [80]. In this study, 
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the authors showed that cell elongation along the grating axis was related to increased 
membrane mobility and decreased activation of LOX-1 receptors, which are used to take 
up harmful oxidized lipids that initiate atherosclerosis. Therefore, proper endothelial cell 
function can be maintained with the use of topographical cues.  
 
Topography and biochemical cues may also be used to capture EPC for repopulation of 
vascular grafts [81]. Nanotopography was demonstrated by Bettinger et al. [82] to 
improve contact guidance, reduce proliferation, increase migration, and enhance 
differentiation and maturation of EPC. Significantly, the in vitro capacity for tubular 
formation of EPCs were not lost after growth on nanogratings with 1.2 µm period and 
600 nm depth [82] and were even enhanced when grown on compliant substrates [83]. 
 
Micro-sized topography has also been demonstrated to selectively inhibit smooth muscle 
cell proliferation and migration, thus preventing intimal hyperplasia of vascular grafts 
[84,85]. Furthermore, various studies have shown that topography, in the form of micro-
sized random roughness [86,87], pillar structures [88] or aligned nanofibers [89] can 
decrease platelet adhesion. The advantages of using topographical cues for guiding 
responses to small diameter vascular grafts are evident, though they have not yet been 
fully explored. 
2.5 Study objectives 
Therefore, in this study, we aim to enhance the bioactivity of PVA small diameter 
vascular grafts through the introduction of topographical and biochemical signals. PVA 
cross-linked with STMP was used as a base material for modification because of its ease 
of fabrication, flexibility for modification and tunable mechanical properties.  
 
First, PVA was patterned through a simple casting method to create planar PVA films 
with various isotropic and anisotropic topographies. The feasibility of incorporating 
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topographies onto the luminal surface of a small diameter vascular graft was also 
assessed. PVA was also modified with attachment factors to enhance its capacity for cell 
adhesion. Thereafter, the effect of topographical and adhesion cues, individually or 
additively, on vascular endothelial cell behavior was examined.  
 
The use of PVA as a platform for therapeutic angiogenesis was also examined through 
the incorporation of PEC fibers on to PVA tubular scaffolds. As a preliminary study, the 
controlled release and bioactivity of VEGF and polyethylene glycol (PEG)-conjugated QK 
peptide from PVA-PEC composite scaffolds were studied.  
 
Finally, a proof-of-concept study to demonstrate the feasibility, compatibility and patency 
of unmodified PVA for small diameter arterial replacement was examined. A novel rabbit 
model of PAD, with perturbation of macro- and micro-circulation, was used. Implanted 








Materials and Methods 
3.1 Preparation of PVA scaffolds 
3.1.1 Activation of PVA for cross-linking 
An aqueous solution of 10% PVA was made by dissolving PVA (Sigma-Aldrich, 85-124 
kDa, 87-89% hydrolyzed) in DI H2O at 121°C for 20 minutes using an autoclave. The 
solution was then thoroughly homogenized by stirring overnight at room temperature. 
The PVA solution was thereafter used or stored at 4°C until further use. To cross-link 
PVA, 12 grams of 10% PVA was mixed with 1000 µl of 15% (w/v) sodium 
trimetaphosphate (Sigma Aldrich). Thereafter, PVA and STMP functional groups were 
activated by adding 400 µl of 30% (w/v) NaOH. The activated PVA solution was 
centrifuged at 1000 rpm for 30 minutes at 25°C to remove bubbles. Afterwards, activated 
PVA was immediately used for casting to create planar films or dip casting to create 
tubular scaffolds.  
3.1.2 Fabrication of patterned molds for PVA casting 
Patterned molds of polydimethylsiloxane (PDMS) with various topographies were 
fabricated from silicon molds using standard methods of soft lithography. Templates 
used in this study had patterns of gratings with dimensions of 250 nm x 250 nm x 250 
nm, 2 µm x 2 µm x 2 µm and 10 µm x 10 µm x 10 µm (groove width, ridge width, depth). 
Concave and convex microlens structures on PDMS with 1.8 µm diameter, 2 µm pitch 
and 0.7 µm sag were also used. PDMS casted on plain tissue culture dish was also used 
as an unpatterned template. Afterwards, 2 cm x 1 cm PDMS molds were used as 
templates for heat embossing of tissue culture polystyrene (TCPS) at 175°C. Each 
patterned TCPS mold was cleaned with ethanol and washed with 0.05% Triton X-100 
before being attached onto one well of a 6-well plate using silicone adhesive. Next, 3.5 
grams of activated PVA was poured into each well and centrifuged at 1000 rpm for 30 
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minutes to force the PVA into the patterned TCPS template. PVA was then desiccated 
for 3 hours and subsequently centrifuged for another 30 minutes at 1000 rpm. PVA was 
dried at a temperature (18°C) and humidity (60-80%) controlled chamber for 5 days to 
allow cross-linking and patterning. Planar patterned PVA films were immersed in sterile 
DI H2O before demolding from the TCPS template. 
3.1.3 Modification of PVA with attachment factor 
To modify PVA with an attachment factor, 14 g of activated PVA was mixed with 400 µl 
of bovine fibronectin solution (Biological Industries; 28.57 µg per g PVA), 400 µl of 
heparin (Leo Pharma; 142.86 U or 0.286 mg per g PVA), 200 µl of RGDS (Sigma-
Aldrich; 28.57 µg per g PVA) or 200 µl of cyclic RGD (CRRGDWLC, Genscript Peptide 
Synthesis; 28.57 µg per g PVA) to cross-link the attachment factor with PVA. Table 2 
summarizes the amount of attachment factor and its hydroxide content added to each 
gram of PVA. Patterning and drying was carried out as described above in section 3.1.2. 
 
Table 2. Summary of PVA modification with attachment factor. Amount of 
attachment factor is given in weight per gram of PVA and as a molar ratio of hydroxyl 
groups added with respect to PVA. 
Attachment factor Molecular weight 
Amount added per 
gram PVA 





Fibronectin 26.24 kDa 28.57 µg/g PVA 1.51:1 
Heparin 12-15 kDa 0.286 mg/g PVA 4.28:1 
RGDS 433.43 Da 28.57 µg/g PVA 600:1 
Cyclic RGD 1008.18 Da 28.57 µg/g PVA 1200:1 
 
3.1.4 Fabrication of PVA tubular scaffolds 
A solid, tubular mold with uniform outer diameter was used as a template for the 
fabrication of patterned and unpatterned PVA tubular scaffolds. Polymer-coated, 
aluminum-based knitting needles (Birch) with outer diameter of 2 mm were used as a 
template for the fabrication of patterned PVA scaffolds. First, a thin film of PDMS was 
spin-coated onto TCPS templates at 1000 rpm for 60 seconds. The thin film was cut to 
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have a width of approximately 7 mm and wrapped around the knitting needle, with the 
pattern facing outwards. The PDMS was attached to the knitting needle such that the 
grating axis matched the longitudinal axis of the knitting needle. Excess PDMS was cut 
off to create a seamless tubular mold. Subsequently, the tubular mold was air plasma 
cleaned for 1 minute at low power (7.16 W) to improve its hydrophilicity and wettability. 
The mold was then immediately immersed in an activated PVA solution and sonicated 
for 1 hour at 57 kHz and 25°C. Afterwards, the mold was removed from the activated 
PVA solution and allowed to dry at 4°C for 10 minutes. A new batch of activated PVA 
solution was thereafter used for multiple dipping, with a 15-minute drying interval in 
between dips. Dip-casting was performed 7 times, creating a total of 8 layers of PVA in 
the tubular scaffold. PVA scaffolds were dried at the same temperature and humidity 
conditions (section 3.1.2) for 3 days. Scaffolds were washed and allowed to swell in DI 
H2O before removing from the tubular mold. A summary of the dip-casting method is in 
Figure 3.1. 
 
Figure 3.1. Dip casting method for creating tubular PVA 
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3.2 Characterization of PVA scaffolds  
3.2.1 SEM analysis of PVA film and PVA tubular scaffold 
To prepare for SEM analysis, PVA planar films and longitudinally-sectioned or cross-
sectioned tubes were air-dried overnight at ambient temperature inside a biological 
safety cabinet. Dry PVA samples were then mounted on aluminum stubs and platinum 
coated (JEOL-JFC 1600 auto-fine coater) at 30 seconds and 30 mA, resulting in 
approximately 10 nm coating thickness. Topographical features of PVA films and tubes 
were then visualized using JEOL-JSM 6010LV scanning electron microscope (SEM) at 
high vacuum and 10 kV electrode voltage. 
3.3 In vitro analysis of PVA planar scaffolds  
3.3.1 Preparation of PVA planar film for cell seeding and blood compatibility assay 
After demolding from TCPS templates, PVA films were cut into 1 cm x 1 cm squares, 
placed into a 24-well plate and sterilized with ultraviolet light (UV) for 20 minutes. To aid 
in cell seeding, PVA films were weighed down by Silastic tubing (Dow Corning), a 
biologically inert material, that fit each well of the 24-well plate. PVA films were 
subsequently sterilized with an aqueous solution of 20% penicillin-streptomycin and 2% 
amphotericin-B in DI H2O to inhibit microorganismal contamination. Upon imminent use, 
PVA films were extensively washed in sterile water to eliminate any residual antibiotic 
and antimycotics. PVA films were then washed with 0.9% clinical grade sodium chloride 
solution (BBraun) and then used for blood compatibility experiments (section 3.3.6). 
Meanwhile, for cell seeding experiments, 500 µl of fetal bovine serum was added to each 
PVA film. Serum and PVA films were centrifuged at 1000 rpm for 30 minutes and 
incubated overnight at 4°C prior to cell seeding (section 3.3.2).  
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3.3.2 Human umbilical vein endothelial cell (HUVEC) culture and PVA planar film 
seeding 
HUVEC (Lonza, passages 3-5) were grown in endothelial basal medium (EBM; Lonza) 
supplemented with the 2MV Single Quot kit (Endothelial growth medium-2MV or EGM-
2MV; Lonza) at standard cell culture conditions of 37°C and 5% CO2. HUVEC were 
washed with HEPES buffered saline solution (10 mM HEPES, 151 mM NaCl, 4.7 mM 
KCl, 2 mM Ca2Cl, 1.2mM MgCl2, 7.8 mM glucose, pH 7.4) and trypsinized using 0.05% 
Trypsin-EDTA to harvest cells. Subsequently, cell count was performed on viable cells 
stained with trypan blue (Invitrogen). A total of 100000 cells in 500 µl EGM-2MV medium 
were added to each PVA film. The cells and the PVA films were centrifuged at 220xg for 
5 minutes and 25°C. Seeded PVA films were incubated in standard culture conditions for 
24 hours. All patterned and unpatterned PVA films were seeded in triplicate for all cell-
seeding experiments, as elaborated below. 
3.3.3 Cell viability and proliferation studies of HUVEC seeded on PVA planar film 
To assess the proliferative capacity of HUVEC on PVA films, the Click-iT EdU assay kit 
(Life Technologies) was used. At 16 hours post-seeding, EdU was added to each PVA 
sample, according to manufacturer’s protocol. PVA samples were then fixed after 8 
hours using 4% paraformaldehyde in phosphate buffered saline (PBS) and stained for 
EdU and nuclei, as per the manufacturer’s instructions. Similarly, cell viability was 
assessed using the Live/Dead assay kit (Life Technologies), with 2 µM Ethidium 
Homodimer and 2 µm Calcein AM, following the manufacturer’s protocol. 
3.3.4 Immunofluorescence studies of HUVEC seeded on PVA planar film 
Assessment of HUVEC functionality and morphology after seeding on PVA films was 
performed using immunofluorescence staining. Twenty-four hours post-seeding, PVA 
films were fixed for 15 minutes using 4% paraformaldehyde in PBS. If necessary, 
permeabilization of cells was performed using 0.1% Triton X-100 in PBS for 15 minutes 
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at 4°C. Meanwhile, blocking of the PVA films was performed using 2% Bovine Serum 
Albumin (BSA) in PBS for 1 hour at room temperature. Thereafter, primary antibodies 
against cell surface (CD31) and intracellular (von Willebrand Factor (vWF), 
phosphorylated focal adhesion kinase (pFAK)) antigens were incubated with the PVA 
films overnight. Secondary antibodies were then added for 1 hour at room temperature. 
The nucleus was visualized using 4',6-diamidino-2-phenylindole (DAPI) and actin fibers 
were visualized using fluorescently labeled phalloidin. Images of HUVEC stained against 
CD31 and vWF were taken using Leica DMIRB inverted microscope, while HUVEC 
stained against pFAK and actin was visualized using Leica SP5 confocal microscope. 
3.3.5 Matrigel assay of cells grown on PVA planar film 
To assess the in vitro angiogenic capacity of HUVEC after growth on PVA planar films, a 
Matrigel assay was employed. Briefly, 50 µl of growth factor reduced Matrigel (BD 
Bioscience) was placed in each well of a 96-well plate and allowed to gel at 37°C for at 
least one hour. PVA films were moved to a new 24-well plate using sterile forceps 24 
hours post-seeding. PVA films were then washed with HEPES buffered saline solution 
and cells were harvested using 0.05% trypsin. Cells grown on the same type of PVA film 
were pooled together and counted using the trypan blue viability stain. Thereafter, 15000 
cells in 150 µl of EGM-2MV medium were placed in each well of Matrigel. Tube 
formation was assessed by phase-contrast optical microscopy at 8 hours post-seeding. 
3.4 Blood compatibility assay for PVA scaffolds 
3.4.1 Blood compatibility assay for PVA planar scaffold  
3.4.1.1 Incubation of platelet rich plasma (PRP) with PVA planar scaffolds 
In vitro blood compatibility assay was performed according to Yim et al. [90]. PVA films 
were prepared beforehand, according to section 3.3.1. Glass coverslips (positive control) 
were coated with collagen overnight at 37°C. Blood samples were collected from 
healthy, New Zealand White rabbits in polypropylene tubes primed with heparin (5U per 
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ml blood). Blood was centrifuged at 100xg for 15 minutes at 22°C. PRP was then added 
to each PVA film at 200 µl per sample and incubated at 37°C for 1 hour at 100 rpm. 
Resting samples of 50 µl PRP alone and 50 µl PRP with anti-platelet disodium 
ethylenediaminetetraacetic acid (EDTA, 5.4 mM) were also included in the experiment. 
Thereafter, PRP was collected for subsequent flow cytometry analysis (section 3.3.6.2), 
while PVA scaffolds were kept for platelet morphology analysis using SEM. Samples 
were washed in ice-cold PBS and fixed using 2.5% glutaraldehyde at 4°C for 2 hours. 
Next, films were dehydrated using a series of increasing ethanol concentration. After 
complete drying, films were then coated and visualized under SEM, as described in 
section 3.2. Blood compatibility assay was done in triplicate for each sample. 
3.4.1.2 Flow cytometric analysis of platelet activation 
After incubation, PRP was collected and placed in 1.5 ml polypropylene tubes and 
diluted with 200 µl of Hepes-Tyrodes buffer (HTB; 137 mM sodium chloride, 2.7 mM 
potassium chloride, 16 mM sodium bicarbonate, 5 mM magnesium chloride, 3.5 mM 
HEPES, 1% glucose, 2% bovine serum albumin, pH 7.4). Platelets were centrifuged at 
17000 rpm for 3 minutes at 22°C and then incubated with antibodies against GPIIb/IIIa 
integrin receptor (Abbiotec). Platelets were then washed with 150 µl HTB and 
centrifuged. Platelets were then incubated with fluorescently conjugated secondary 
antibody. Samples were fixed with 2% paraformaldehyde in HTB for 10 minutes. 
Platelets were then centrifuged and replaced with HTB then subsequently analyzed 
within 24 hours for scatter characteristics and expression of markers using BD LSR 
Fortessa. (BD Bioscience). Flow cytometry data was analyzed using FlowJo 4.0. 
3.4.2 Blood compatibility assay for PVA tubular scaffolds 
3.4.2.1 Incubation of PRP with tubular scaffolds 
Gamma-irradiated PVA vascular grafts (1 mm diameter), Silastic tubing (Dow Corning), 
gamma-irradiated industrial grade ePTFE tubing (Zeus), were weighed and washed in 
sterile 0.9% saline solution (BBraun). PRP, harvested and prepared as detailed in 
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section 3.4.1, was then added to each tubular sample at 0.75 µl per mg sample and 
sealed at both ends with luer lock combistoppers (BBraun) or vascular anastomosis 
double clamps (Bear Surgical). Glass beads coated with bovine collagen I (Invitrogen; 
7.15 µg per mg sample) overnight at 37°C were included as a positive control and 
incubated with PRP in a polypropylene (PP) tube. Subsequently, samples were 
incubated for 1 hour at 37°C, 100 rpm. Control resting samples of 100 µl PRP alone and 
100 µl PRP with anti-platelet disodium EDTA (5.4 mM) were also included. Thereafter, 
PRP was collected for subsequent flow cytometry analysis (same as section 3.4.1.2), 
while samples were kept for platelet morphology analysis using SEM (same as section 
3.4.1.1). Assay was done in triplicate for each sample. 
3.5 Incorporation of VEGF into PVA vascular graft using PEC fiber 
Polyelectrolyte complexation (PEC) is a self-assembly process that occurs at the 
interface of two oppositely charged polyelectrolytes [91]. PEC fibers have been used for 
the precise spatiotemporal delivery of growth factors [92-94], cells [93-95] and drugs 
[92]. In addition, PEC fibers protect encapsulated biologics thus, retaining bioactivity 
after a prolonged period of time. PEC fibers were explored as a vehicle for the controlled 
release of angiogenic factors from PVA vascular grafts.  
3.5.1 Fabrication of PVA-PEC composite tubular scaffolds with VEGF 
Chitosan (Low molecular weight, >75% acetylation, 20-300 cps; Sigma-Aldrich) was 
purified as described previously [92]. Purified chitosan was dissolved in 0.15 M acetic 
acid solution at 1% (w/v) and subsequently adjusted to pH 6. Recombinant Human 
VEGF-165 (Invitrogen) was reconstituted in 0.05% (w/v) heparin in DI water to a final 
concentration of 2 µg/µl. To encapsulate VEGF in PEC fibers, 7.5 µg VEGF was added 
to 1% chitosan (15 µl). The total amount of VEGF encapsulated was based on the 




Alginate (Alginic acid sodium salt from brown algae; Sigma-Aldrich) and heparin 
(Heparin sodium salt from porcine intestinal mucosa, Sigma-Aldrich) were both prepared 
by dissolving in sterile DI water at 1% (w/v). Both solutions were then filtered (0.2 µm 
pore size) and mixed together at an optimised ratio of 9:1 alginate:heparin. The addition 
of heparin to the polyelectrolyte solution has been shown to attenuate the burst release 
of heparin-binding growth factors like VEGF [92]. Alginate-heparin solution (22.8 µl) and 
chitosan-VEGF (18.5 µl) solution were placed on a hydrophobic surface. Using forceps, 
the polyelectrolyte solutions were brought together to form a continuous fiber. The fiber 
was slowly drawn upward and anchored to either a PVA tubular scaffold with 4 layers (1 
mm ID; PVA-PEC composite) or a bare tubular mold. The tubular scaffold or mold was 
attached to a speed-controlled rotor, rotating at a rate of 0.0313 Hz. PEC fiber was spun 
around the circumference of the tubular mold while the polyelectrolyte solution was 
actuated along the long axis of the PVA graft at 2.5 mm/h.  By actuating the 
polyelectrolyte solution, the PEC fibers were placed in the mid-section of the graft, 
spanning a total of 5 mm. Concentration of PEC fibers were necessary to ensure that 
anastomosis of the PVA graft to the native vessel were not hampered by the PEC fibers. 
To measure encapsulation efficiency, 500 µl of PBS was used to collect the residual 
solution upon fiber termination. The PEC fibers were allowed to dry at 4°C. 
Subsequently, the PVA-PEC composite scaffolds were dip-coated with two additional 
layers of PVA, thus creating a composite scaffold with a total of 6 layers of PVA. A 
summary for fabricating the PVA-PEC composite scaffold is given in Figure 3.2. 
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3.5.2 Controlled release of VEGF from PVA-PEC composite scaffold 
Each PVA-PEC composite scaffold and PEC standalone fiber sample were placed in a 
24-well plate with 500 µl of 0.5% BSA in EBM. EBM was used as a release solution so 
that it could be directly used in the VEGF bioactivity assay (section 3.5.3). Meanwhile, 
BSA was added to stabilize released VEGF [96] and prevent its excessive adsorption to 
plastic surfaces. Controlled release study was carried out at 37°C and 5% CO2. Release 
solution was collected at several timepoints with complete replacement of the release 
medium. The amount of VEGF released at different timepoints was measured using 
Human VEGF enzyme-linked immunosorbent assay (ELISA) Kit (Invitrogen). Each 
sample was assessed in quadruplicate. 
3.5.3 VEGF Bioactivity assay  
To assess the bioactivity of the released VEGF, an endothelial cell proliferation assay 
was carried out. HUVEC were seeded onto 96-well plate at 3000 cells per well and 
cultured for 24 hours. Cells were then serum-deprived for 24 hours using EGM-2MV with 
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0.5% Fetal Bovine Serum (FBS; Lonza). Afterwards, medium was replaced with 50 µl 
release solution from different timepoints supplemented with an equal volume of 2X 
concentrated EGM-2MV. AlamarBlue (Invitrogen) cell viability assay was carried out at 
day 2 to determine the level of cell proliferation, as compared to cells grown in the 0.5% 
BSA in EBM solution (negative control). Cell proliferation was reported as a percentage 
of the positive control. Each release medium sample was tested in triplicate. 
3.6 Incorporation of QK-PEG into PVA vascular graft using PEC fiber 
3.6.1 Conjugation of QK peptide with PEG 
PEC fibers for small molecule drug release (300 Da) showed rapid and complete release 
within 3 hours [92]. Moreover, our preliminary results using PVA-PEC composite 
scaffolds revealed the ideal molecular weight for release to be around 14-15 kDa. To 
obtain a near-constant release rate, the VEGF mimic QK peptide (sequence 
WQELYQLKY; 1.27 kDa; GenScript Peptide Synthesis) was conjugated to either biotin-
PEG-NHS (10kDa, >95% purity, substitution purity >80%; NANOCS) or MPEG-
Succinimidyl-NHS (10kDa, >95% purity, substitution purity >90%; NANOCS) based on 
the specific conjugation of the peptide N-terminus to the N-hydroxysuccinimide (NHS) 
moiety. The conjugation method and assessment of the QK-PEG bioactivity is detailed 
further in Appendix C. By specifying the ratio between QK-PEG and QK-PEG-biotin 
conjugates, the measurement of encapsulation and controlled release was approximated 
from measurement of QK-PEG-biotin alone (section 3.6.3). 
3.6.2 Fabrication of PVA-PEC composite scaffold with QK-PEG 
A total of 27 µg of QK-PEG and 2.7 µg QK-PEG-biotin (10:1 ratio) was added to 1% 
chitosan (46 µl) solution for encapsulation into PEC fibers. The amount of QK-PEG 
encapsulated was determined from the equivalent molar concentration of QK that elicits 
the same angiogenic response as VEGF [97,98]. Alginate (1% w/v, 61µl) was drawn 
against the polycation solution for fiber formation. Similar to section 3.5.1, PEC fibers 
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were drawn and spun onto PVA tubular scaffold with 4 layers. In contrast to PVA-PEC 
composite scaffolds with VEGF, PEC fibers with QK were spun at a bi-directional angular 
orientation with respect to the longitudinal axis of the PVA scaffold (Figure 3.3). A 
syringe pump was used to actuate the polyelectrolyte solutions at a speed of 8.57 
mm/min, with the rotation of the PVA tubular scaffold fixed at 0.07825 Hz. Upon fiber 
termination, residual polyelectrolyte solution was collected with 500 µl of PBS. PEC 
fibers were allowed to dry for 5 minutes before 4 layers of PVA were added. 
 
3.6.3 Controlled release of QK-PEG from PVA-PEC composite scaffolds 
Controlled release of QK-PEG was performed simultaneously in two different release 
media. One set of samples was immersed in 500 µl of sterile PBS with 0.05% sodium 
azide. A second set of samples were immersed in 500 µl of EBM with 1% FBS (Lonza) 
and 1% GA-1000 (Lonza). All samples were placed in 24-well plates and incubated at 
37°C with 5% CO2 and 95% humidity. Release solution was collected at various 
timepoints and replaced with fresh solution. All controlled release experiments were 
performed in triplicate. The amount of release medium was measured using the EZ 
Biotin Quantification Kit (Thermo Scientific). Each controlled release medium was 
quantified in triplicate. 
 
Figure 3.3. Comparison of PVA-PEC composite 












3.6.4 QK-PEG bioactivity 
QK-PEG released in solution comprising of EBM with 1% FBS and GA-1000 was then 
used to determine its bioactivity. HUVEC (2000 cells/well) were seeded in 96-well plates 
and cultured for 24 hours with EGM-2 (Lonza). After 24 hours, cells were serum deprived 
with EBM containing 1% FBS and 0.4% hydrocortisone. Twenty-four hours afterwards, 
medium was replaced with 40 µl release medium from various timepoints supplemented 
with 4 µl FBS. Medium was then replaced after 1 day with release medium from the 
same timepoint. Alamarblue assay was then conducted at day 3. Each controlled release 
medium was assessed in triplicate. 
3.7 In vivo implantation of PVA small diameter vascular graft in novel PAD model 
3.7.1 Fabrication of PVA small diameter vascular grafts for in vivo implantation 
PVA small diameter vascular grafts were created for implantation into a rabbit femoral 
artery. Hypodermic needles with outer diameters of 0.9 mm and 1 mm were oxygen 
plasma treated (Femto Science CUTE-B Plasma Treatment System) with 8 ml/min O2 
gas at 60W for 1 minute. Needles were then dip-casted using activated PVA solution a 
total of 6 times, as elaborated in section 3.1.4. After drying, the scaffolds were then 
washed in water to allow easy removal of the PVA from the needles. PVA tubular 
scaffolds were then sterilized by gamma irradiation (25 kGray) before implantation into 
an animal model.  
3.7.2 Surgical work for implantation of PVA vascular graft 
The preliminary in vivo study was done in accordance with the Institutional Animal Care 
and Use Committee of the National University of Singapore. Male New Zealand White 
rabbits, weighing 3.5-4.0 kg, were used for implantation of PVA vascular grafts in the left 
femoral artery. Animals were sedated with ketamine (25 mg/kg) and medetomidine (0.02 
mg/kg), intubated and subsequently maintained on 2-5% isoflurane and 12 ml/min/kg O2 
gas. Prophylactics of enrofloxacin (5 mg/kg) and buprenorphine (0.04 mg/kg) were 
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administered intramuscularly before surgery. Intravenous infusion of 0.9% sodium 
chloride (5 ml/kg/hr) was given. Papaverine (1.43 mg/ml) was administered topically and 
intravascularly to improve visualization of the left femoral artery. To mimic occlusion of 
peripheral arteries, 150-250 µm embolic particles (Boston Scientific) resuspended in 1:1 
saline and 4% gelofusine (BBraun) were administered intravascularly through the left 
femoral artery. The use of a novel PAD animal model is detailed in Appendix C. The right 
femoral artery of each rabbit was used as its normal internal control. Subjects in the 
treatment group (n=3) received the PVA small diameter vascular graft with either 0.9 mm 
or 1 mm ID and 4 mm length (Figure 3.4 B and D), where the choice of graft diameter 
implanted depended on the caliber of the femoral artery of each rabbit. PVA vascular 
grafts were anastomosed to temporally ligated femoral artery using simple interrupted 
sutures of nylon 9-0 or 10-0. Ligation time for all surgeries involving PVA vascular graft 
implantation did not exceed 3 hours, to minimize irreversible ischemic damage and 
reperfusion injury.  During this period, heparin (100IU/kg) was administered 
intravenously. Post-anastomotic patency was confirmed by refill test and visual 
observation of pulsation in the post-anastomotic vessel. On the other hand, negative 
control rabbits (n=3) underwent permanent ligation and resection of a segment of the 
femoral artery, thereby inducing permanent hindlimb ischemia (Figure 3.4 C and E). All 
subjects were treated with enrofloxacin (5 mg/kg) and buprenorphine (0.04 mg/kg) for 7 




3.7.3 Post-operative assessment 
Graft patency and collateral formation were estimated by measuring the surface 
perfusion of the front part of the foot (dorsal foot) using a laser Doppler flowmeter 
(Perimed PeriFlux System 5010 Laser Doppler Perfusion Monitoring System, 1 mm 
diameter fiber optic probe PR407-1 with a 0.2 s time constant). Measurements were 
performed on subjects sedated with 17.5 mg/kg medetomidine and 0.02 mg/kg 
medetomidine. To ensure consistency, laser Doppler measurements were performed on 
the same location, as marked by a small circular tattoo (AIMS animal tattoo identification 
product) on clean, shaven dorsal foot. For comparison, laser Doppler imaging (Perimed 
PeriFlux PIM 3 Imaging System) was also performed on the same marked spot 
(Appendix C).  
 
 
Figure 3.4. Schematic diagram for rabbit model of PAD. PAD was induced in rabbit 
model by injection of bolus dose of embolic particles. (A) Overview of rabbit circulatory 
system. (B) Small diameter PVA graft (0.9 or 1 mm ID) was then anastomosed to 
resected left femoral artery. (C) Negative control subjects underwent ligation of femoral 
artery to induce permanent hindlimb ischemia. (D) Representative image of PVA graft 
implanted on to rabbit left femoral artery. (E) Representative image of femoral artery 
ligation in a negative control subject. Black arrows show the ends of the ligated artery. 
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Left dorsal foot surface perfusion (PAD limb) was expressed as surface perfusion 
percentage normalized to that of the right dorsal foot (normal limb). Patency of the graft 
was validated by digital subtraction angiography (GE Innova series 2100) at the endpoint 
using contrast agent (GE Healthcare Omnipaque solution 350 mg I/ml) mixed with 0.9% 
sodium chloride solution at a 1:1 ratio. A midline incision was made to cannulate the 
caudal abdominal aorta (near the iliac bifurcation) for direct delivery of contrast agent. 
Imaging of each hindlimb was done separately while the contralateral hindlimb was 
clamped temporarily, starting with the PAD hindlimb. Digital image analyses of 
angiography videos were performed, as described in detail in Appendix D. 
3.7.4 Histological analysis 
Heparin (100 IU/kg) was administered systemically before euthanization with sodium 
phentobarbital (150 mg/kg). Tissues from the hindlimb enclosing the PVA graft or the 
ligature were then harvested and fixed with 4% paraformaldehyde in PBS for 48 hours. 
Tissues were subsequently processed and embedded in paraffin using routine 
histological procedures. Sections 15-20 µm thick were stained with hematoxylin and 
eosin (H&E). Sections were also stained with antibodies against CD31 (Abcam) and 
alpha-smooth muscle actin (α–SMA; Abcam), to determine endothelialization of graft and 
collateral formation [99] via immunohistochemistry (IHC) staining using Leica Novolink 
Min Polymer Detection System. Optical images were taken using Nikon Eclipse Ti-S 
microscope and NIS Element camera software at various objectives.  
3.8 Statistical analysis 
Data were reported as mean ± standard deviation. Statistical analysis using one-way 
ANOVA with Tukey’s test, which compared each mean with every other mean, were 






Results and Discussion – In vitro characterization of patterned 
and modified PVA scaffolds 
PVA hydrogel has been shown to have excellent and tunable mechanical properties that 
make it an advantageous biomaterial for small diameter vascular grafts. However, the 
hydrophilicity of PVA limits protein adsorption and consequently, cell adhesion. The 
modification of PVA is necessary for in situ endothelialization, which will lead to improved 
hemocompatibility, inhibition of intimal hyperplasia and long-term clinical patency of PVA 
small diameter vascular grafts. In this chapter, we incorporated topographical and 
attachment factors on to PVA hydrogel and examined endothelial cell growth and platelet 
activation on the modified PVA scaffolds. 
4.1 Results 
4.1.1 Patterning of planar and tubular PVA scaffolds 
Figure 4.1 shows the various topographies on planar PVA films. Anisotropic gratings with 
dimensions of 2 µm x 2 µm x 2 µm, 10 µm x 10 µm x 10 µm and 250 nm x 250 nm x 250 
nm (ridge width x groove width x depth) and isotropic microlens patterns with 1.8 µm 
diameter, 2 µm pitch and 700 nm sag were patterned onto PVA with excellent fidelity and 
integrity. Similarly, topographies were well replicated onto the luminal surface of the 
tubular hydrogel scaffolds (Figure 4.2), with the exception of the 250 nm gratings. For 
this reason, PVA scaffolds with 250 nm gratings were not further evaluated in vitro. The 
remaining patterns, successfully replicated on both planar and tubular scaffolds, were 
tested on supporting endothelial cell growth and phenotype. Patterned planar PVA films 





Figure 4.1. Patterning of planar PVA films. PVA films were patterned with anisotropic gratings 
(250 nm x 250 nm x 250 nm; 2 µm x 2 µm x 2 µm; 10 µm x 10 µm x 10 µm; ridge x gap x height) 
and isotropic microlens (1.8 µm diameter, 2 µm pitch, 0.7 µm sag) topographies. 
 
 
Figure 4.2. Patterning of tubular PVA scaffolds. PVA tubular scaffolds (ID of 2 mm to 2.25 mm) 
were patterned with anisotropic gratings (250 nm x 250 nm x 250 nm; 2 µm x 2 µm x 2 µm; 10 µm 
x 10 µm x 10 µm; ridge x gap x height) and isotropic microlens (1.8 µm diameter, 2 µm pitch, 0.7 
µm sag) topographies. Inset in each image shows the macroscopic view of the tubular scaffold. 
Red arrow denotes grating axis. 
Figure 2. Patterning of tubular PVA scaffolds. PVA tubular scaffolds (internal diameter of 2 mm to 2.25 mm) 
were patterned with anisotropic gratings (250 nm x 250 nm x 250 nm; 2 µm x 2 µm x 2 µm; 10 µm x 10 µm x 10 
µm; ridge x gap x height) and isotropic microlens (1.8 µm diameter, 2 µm pitch, 0.7 µm sag) topographies. Inset 
in each image shows the macroscopic view of the tubular scaffold. White arrow denotes grating axis. 
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4.1.2 Endothelial cell viability and proliferation on patterned PVA scaffolds 
To analyze the effect of topographical cues on endothelial cells, HUVEC were seeded 
onto patterned planar PVA substrates. After 24 hours, HUVEC were analyzed for viability 
and proliferative capacity (Figure 4.3). Viability of HUVEC improved on PVA films with 
topographical cues in comparison to the unpatterned control. Anisotropic topographies of 
2 µm and 10 µm gratings showed the most change in viability and proliferation, but were 
not found to be significant. Similarly, the proliferative capacity of HUVEC was enhanced 
after growth on patterned PVA planar films, albeit HUVEC on the convex microlens 
topography has shown the highest proliferation rate. 
 
 
Figure 4.3. Improvement of endothelial cell viability and proliferation on planar 
PVA films with topography. Cell viability is given as ratio of fluorescent signal from 
live (calcein-AM positive cells) over dead (Ethidium homodimer-1 positive cells) cells. 
Proliferation rate is given as percentage of cells with EdU uptake over total number of 
cells. Endothelial cells had better viability and proliferation when cultured on patterned 
PVA films after 24 hours. Error bars represent standard deviation. 















































































4.1.3 Endothelial cell phenotype on patterned PVA scaffolds 
HUVEC were also immunostained for CD31 and vWF to assess the endothelial cell 
phenotype (Figure 4.4). HUVEC retained the expression of CD31 in the cell periphery 
when grown on PVA with convex microlens and 10µm gratings (Figure 4.4A). On the 
other hand, CD31 on HUVEC grown on unpatterned PVA films showed more diffuse 
staining that is not localized to the cell periphery. Similarly, characteristic punctuate vWF 
staining was observed in HUVEC cultured on PVA with microlens and 2 µm gratings 
(Figure 4.4B). Meanwhile, HUVEC on unpatterned control less punctuate vWF staining, 
while HUVEC on 10 µm gratings lack punctuate staining.  
4.1.4 Endothelial cell function on patterned PVA scaffolds 
After growth on PVA films, HUVEC were harvested and examined for in vitro angiogenic 
capacity using a Matrigel assay. Cells grown on patterned PVA exhibited better tube 
formation after 8 hours on Matrigel (Figure 4.5). Specifically, cells on convex microlens 
showed the best tubular structure formation. HUVEC on concave microlens and 10 µm 
gratings also exhibited some tube formation. Cells harvested from unpatterned control 
and 2 µm gratings on PVA lack interconnected tubes and most of the cells were found in 
clumps. Overall, the microlens structure and the 10 µm gratings structure seem to be the 






Figure 4.4. Retention of endothelial cell phenotype on planar PVA films with topography.  
Endothelial phenotype markers CD31 (A) and vWF (B) were detected using immunofluorescence 
staining. Nuclei were detected by using DAPI. More endothelial cells retained expression of CD31 
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Figure 4.5. Retention of endothelial cell in vitro angiogenic capacity after culture on 
patterned planar PVA films. Endothelial cells were first grown on planar PVA scaffolds for 24 
hours. Endothelial cells were then harvested and seeded on Matrigel, where it exhibited tubular 
structures after 8 hours. Tubular formation was enhanced in endothelial cells that were grown on 
10 µm gratings and microlens structures compared to unpatterned control. Scale bar =  200 µm. 
 
4.1.5 Blood compatibility of patterned planar PVA films  
Blood compatibility of patterned PVA films were assessed using an in vitro assay that 
measures microparticle release from activated platelets by detecting expression of 
GPIIb/IIIa integrin receptor (Figure 4.6). In comparison to glass, patterned and 
unpatterned PVA films showed a lower amount of platelet activation (Figure 4.6A). More 
profound differences were observed in platelet morphologies (Figure 4.6B), where 
platelets attached to unpatterned PVA surfaces exhibited a more fibrous morphology, 
with multiple extensions for each platelet. Platelets on unpatterned PVA were also mostly 
aggregated, indicative of a more activated phenotype. In contrast, platelets attached to 












Figure 4.6. Improvement of blood compatibility on patterned planar PVA by 
decreasing platelet activation. (A) Number of activated platelets as measured by 
microparticle formation. Number of microparticles formed by platelets on PVA was 
lower than that from glass coverslip. Error bars represent standard deviation. (B) 

















































4.1.6 Modification of PVA with attachment factors 
To further improve the functionality of PVA, various attachment factors were cross-linked 
with PVA. Figure 4.7 shows the roughness of the modified PVA films. Fibronectin-, 
RGDS- and cRGD-modified PVA films show a very smooth surface. On the other hand, 
heparin-modified PVA films show a very rough structure, with structures that appear as 
very shallow pits. Gross observation and handling of heparin-PVA films show apparent 
reduction in elasticity and strength of the material compared to the unmodified PVA. On 
the other hand, no gross change in mechanical property was observed for fibronectin-
PVA, RGDS-PVA and cRGD-PVA films. 
 
 
Figure 4.7. Modification of planar PVA with biochemical cues. SEM 
images show random roughness of PVA films modified with biochemical 
cues. Inset shows higher magnification image of heparin-PVA films. 
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4.1.7 Endothelial cell viability and proliferation on modified PVA films 
The addition of attachment factors to PVA films increased endothelial cell viability and 
endothelial cell proliferation (Figure 4.8). Specifically, both RGDS-PVA and cRGD-PVA 
had marked effects on both endothelial cell viability and proliferation. On the other hand, 
fibronectin-PVA films did not have an effect on endothelial cell viability despite increasing 
endothelial cell proliferation. Surprisingly, heparin did not improve the viability or 
proliferation of endothelial cells in comparison to the unpatterned control.  
 
 
Figure 4.8. Improvement of endothelial cell viability and proliferation on planar PVA 
films modified with attachment factors. Cell viability is given as ratio of fluorescent 
signal from live (calcein-AM positive cells) over dead (Ethidium homodimer-1 positive cells) 
cells. Proliferation rate is given as percentage of cells with EdU uptake over total cell 
number. Endothelial cells had better viability and proliferation when cultured on modified 
PVA films. Heparin-PVA did not have a positive effect on endothelial cell viability and 
proliferation. Error bars represent standard deviation. 
 
4.1.8 Endothelial cell phenotype on modified PVA films 
CD31 expression of endothelial cells grown on all modified films exhibited characteristic 
surface marker expression (Figure 4.9). Punctuate and abundant vWF staining was 
noted on endothelial cells grown on heparin-PVA and RGDS-PVA films. HUVEC on 
cRGD-PVA showed some vWF expression while those on fibronectin-PVA films were 













































































































































































































































































































































































































4.1.9 Endothelial cell function on modified PVA films 
Matrigel assay demonstrated the excellent tube formation capability of endothelial cells 
that were grown on fibronectin-PVA, RGDS-PVA and cRGD-PVA films (Figure 4.10). 
Endothelial cells from RGDS-PVA films show interconnected and extensive tubular 
structures. On the other hand, both heparin-PVA and unmodified PVA films did not 
support the retention of the angiogenic capacity of endothelial cells, as shown by the lack 
of interconnected tube structures. 
 
 
Figure 4.10. Retention of endothelial cell in vitro angiogenic capacity after culture on 
modified planar PVA films. Endothelial cells were first grown on planar PVA scaffolds for 24 
hours. Endothelial cells were then harvested and seeded on Matrigel, where it exhibited tubular 
structures after 8 hours. Tubular formation was enhanced in endothelial cells that were grown on 
RGDS and fibronectin modified PVA films. Scale bar = 200 µm. 
4.1.10 Biochemical and topographical modification of PVA 
The dual incorporation of an attachment factor and topographical cue on PVA planar 
films are shown on Figure 4.11. Cross-linking of cRGD with PVA did not interfere with 
the patterning of PVA, as all topographies were well replicated. Changes in transparency 







Subsequently, the effect of the attachment factor and topography incorporation on 
HUVEC was then assessed in terms of cell viability and adhesion. 
 
 
Figure 4.11. Patterning of planar PVA films modified with cRGD. SEM 
images of planar films show good fidelity of topographical structures 
replicated on cRGD-modified PVA. 
4.1.11 Endothelial cell viability on patterned cRGD-PVA films 
Figure 4.12 shows the differences in HUVEC viability on cRGD-PVA with various 
topographies. In general, HUVEC grown on patterned cRGD-PVA films exhibited 
increased viability, in contrast to unpatterned cRGD-PVA. Expectedly, the viability of 
endothelial cells cultured on patterned cRGD-PVA was enhanced in contrast to 
unpatterned cRGD-PVA or unmodified and unpatterned PVA. Moreover, the effect of 
both topography and modification on HUVEC viability was most apparent on convex and 












Figure 4.12. Endothelial cell viability on planar 
patterned and cRGD-PVA scaffolds. Comparison 
between patterned and cRGD and unmodified PVA. * 
denotes statistically significant difference (p < 0.05) 
compared to unpatterned PVA film. ‡ denotes 
statistically significant difference (p < 0.05) between 
films with the same topography but with different 
modification. 
4.1.12 Expression and localization of pFAK on HUVEC grown on patterned cRGD-PVA 
films. 
HUVEC on patterned cRGD-PVA films exhibited punctuate and organized pFAK 
structures, similar to those found on cells grown on glass coverslip (Figure 4.13). This 
was most apparent for HUVEC on cRGD-PVA with gratings. Meanwhile, pFAK on 
unmodified PVA with 2 µm and 10 µm gratings exhibited a more diffuse organization. 
This trend was consistent for HUVEC on unmodified PVA, regardless of topography. For 
HUVEC grown on cRGD-PVA with concave microlens, the difference in amount of pFAK 
expression is evident. Changes in the actin cytoskeleton and nuclear size were also 
observed. Some HUVEC on cRGD-PVA with 10 µm gratings exhibited organized actin 



































































































































































































































































































































Similarly, some HUVEC on the 2 µm cRGD-PVA films had elongated nuclei. In contrast, 
HUVEC on unmodified PVA with gratings did not show any elongation throughout. On 
cRGD-PVA with microlens, actin was circumferentially arranged at the cell periphery and 
nuclei were larger than those on the unmodified PVA films. A parallel trend of nuclear 
size difference was found between HUVEC on unpatterned cRGD-PVA and unpatterned 
unmodified PVA. Endothelial cell nuclei on unmodified PVA were generally smaller than 
those found on cRGD-PVA, indicative of imminent cell death. 
4.2 Discussion  
4.2.1 Patterning of PVA using a novel casting method 
In this study, we employed both biophysical and biochemical cues to improve the 
bioactivity of PVA scaffolds. First, we demonstrated the ease of modifying PVA with 
topographical cues. The patterning of planar PVA hydrogel using the solvent casting 
method yielded topographies with very high fidelity and integrity in both micrometer and 
nanometer range. We found that by varying cross-linking parameters, the surface 
roughness and the integrity of replicated structures on the PVA planar films can be 
modified. PVA cross-linking, which depends on the local concentration of NaOH and 
STMP in an aqueous environment [6,100-102], was easily controlled. We speculate that 
a decrease in the rate of cross-linking gives sufficient time for the material to flow into the 
patterned molds before PVA chains are cross-linked and immobilized. In a previous 
study wherein PVA was rapidly heat-cured on a patterned silicon mold, structure 
resolution was limited to only 50 µm because of rapid shrinkage of the hydrogel [103]. By 
sufficiently slowing the rate of cross-linking, PVA molecules may still be rearranged to 
follow topography on the molds. Using this method and a suitable hydrophilic mold, 
potentially any pattern can be replicated on PVA. The limit of resolution to planar PVA 
patterning using the solvent casting method remains to be discovered. It should be 
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noted, however, that the successful patterning on planar PVA did not always translate to 
replication fidelity in the tubular scaffolds, as seen for the 250 nm gratings structures.  
 
Similar methods for hydrogel patterning use PDMS templates and in situ photo-induced 
cross-linking to create patterned hydrogel made up of natural [7,104] and synthetic 
polymers [105,106]. However, these methods were only able to demonstrate the 
patterning method for submicron-scale structures. This method was most possibly limited 
by the rapid cross-linking after exposure to UV light. Other methods for patterning 
hydrogel involve photolithography on photo-cross-linkable polymers like PEG [107] or 
methacrylated gelatin [108]. The resolution using photolithography is, likewise, 
constrained by the limit of optical diffraction [109]. Laser micropatterning, using high-
energy lasers that can break chemical bonds and etch patterns, was also previously 
used to pattern PVA hydrogel [110]. Aside from being limited in resolution, both 
photolithography and laser micropatterning require specialized equipment to deliver high-
energy radiation [109]. In contrast, embossing and soft lithographic techniques employed 
in our PVA patterning method merely require common lab equipment and materials 
easily accessible to all laboratories. 
 
Numerous studies show the value of topographical cues for vascular tissue engineering. 
With the exception of electrospun scaffolds with aligned nanofibers [41,76,111-116], no 
one has demonstrated the incorporation of valuable topographical cues in the luminal 
surface of an actual small diameter vascular graft. We showed the novel patterning of a 
tubular scaffold through the use of a novel dip-casting method in this study. We also 
showed the novel method for the simultaneous luminal patterning and molding of a small 
diameter vascular graft. A primary advantage to this method is the creation of a 
seamless, tubular scaffold. This is necessary for creating a uniform, continuous scaffold 
that will maintain laminar flow in the graft and prevent inadvertent flow stasis and platelet 
activation. Besides, the dip-casting method is also amenable for high-fidelity replication 
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of topographies on the luminal surface. While Jose et al recently demonstrated the use 
of an oscillating electric field for alignment of electrospun nanofibers to fabricate a 
seamless tube [116], their method is limited to fibrous topographies. In comparison, the 
use of thin film PDMS template, which can be easily replicated using standard soft 
lithographic methods, permits a wide variety of topographies to be incorporated into the 
luminal surface of tubular scaffolds using our dip-casting method. Therefore, 
topographies with various geometries that were previously shown to have positive effects 
on endothelial cell behavior, such as organized pillars [117] or randomly oriented cones 
[118], can now be incorporated into small diameter vascular grafts.   
 
A possible limitation to this technique is the changes in the dimensions of topography 
that may be inadvertently introduced by curving of the PDMS template. Although we did 
not observe a significant difference in dimensions between planar and tubular scaffolds, 
it should be taken into account when translating in vitro results to preclinical or in vivo 
studies. Liliensiek et al. [8] have shown that endothelial cells are sensitive to changes in 
topography dimension as small as 400 nm [8]. Furthermore, as mentioned above, our 
technique is currently limited to the micrometer range. Gratings with 250 nm dimensions 
were not replicated well on the tubular scaffold, despite having good fidelity on planar 
PVA scaffolds. The wettability of the PDMS surface, in contrast to that of TCPS, may 
prevent proper filling of activated PVA solution into 250 nm gratings structures. The 
fabrication of the tubular mold can also only be done presently for rods not smaller than 
2 mm diameter. A uniform tubular mold with fixed diameter and pattern etched on a 
hydrophilic surface may be able to improve our patterning method.  
 
4.2.2 Incorporating attachment factors in PVA 
The inherent hydrophilicity of PVA hydrogel prevents serum protein adhesion and deters 
cell adhesion [61,119,120]. Therefore, biomolecules with cell attachment functions were 
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also cross-linked with PVA using STMP. Fibronectin is a well-known ECM component 
and stimulus for endothelial cell adhesion that binds cell-surface integrins through its 
RGD moiety [121]. RGDS is a tetrapeptide derivative of fibronectin, while cRGD is a 
more stable and potent cyclic peptide derivative. The use of these three attachment 
factors for the covalent modification of different biomaterial surfaces is well documented 
(section 2.4). In addition, heparin was used to improve the surface chemistry of the 
material and promote serum protein adsorption. 
 
The incorporation of biochemical cues in PVA was performed through direct mixing of 
these factors into the activated PVA solution. We postulated that these attachment 
factors would be tethered by cross-linking with the activated hydroxyl groups on PVA. 
According to Lack et al. [100], cross-linking of PVA with STMP proceeds first through the 
reaction of the pendant hydroxyl group on PVA with NaOH, forming the alcoholate group. 
The alcoholate group or NaOH in the solution then opens the STMP ring, resulting in 
polymer grafted sodium tripolyphosphate (STPP) or simple STPP, respectively. Reaction 
of another alcoholate group with grafted STPP forms a monophosphate linkage to 
connect PVA moieties. The same activation process presumably transpires on the 
multiple hydroxyl side chains of the attachment factors, resulting in its attachment to 
PVA. Our method for cross-linking biochemical cues therefore, is applicable to other 
proteins and attachment factors not included in this study. For instance, gelatin, a 
partially denatured derivative of the ECM protein collagen, was previously incorporated 
into PVA using the same method [102]. Other proteins, which are inherently rich in 
hydroxyl side chains, could be incorporated with PVA. For example, growth factors for 
stimulating endothelial cell migration and proliferation, such as VEGF, may be 
immobilized. Other synthetic polymers with available hydroxyl groups may additionally be 
used to reduce the bulk hydrophilicity and improve protein adhesive properties of the 
material. On the other hand, short peptide moieties, such as cRGD or RGDS, with only 
one or two hydroxyl side chains per molecule, respectively, may pose a problem for 
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formation of the cross-linked PVA network because of limited number of hydroxyl 
sidechains for tethering PVA. However, we speculate that the amount of peptides that 
we added did not significantly interfere with PVA cross-linking, as gross mechanical 
properties were similar to those of unmodified PVA. 
 
Other studies previously modified PVA using multi-step chemical reactions, often 
involving organic or toxic substances. Perhaps the first instance of PVA modification was 
demonstrated by Kobayashi et al, who used the toxic compound cyanogen bromide to 
bind collagen and fibronectin to PVA hydroxyl groups [122]. PVA has, likewise, been 
modified with fibronectin using a multi-step process that involves activation of hydroxyl 
groups followed by its alkylation and nucleophilic attack by fibronectin amine groups 
[61,123]. Schmedlen et al. and Rafat et al. modified photocross-linkable PVA with RGDS 
[124] or RGD peptide [119], requiring tedious modification of both PVA and the 
biomolecule. Similarly, grafting methacrylate groups first on both molecules and 
subsequent cross-linking through UV can be used to make heparin-PVA scaffolds [125]. 
For these methods of PVA modification, multiple chemical reactions were necessary to 
arrive at the final product, which leads to losses, low yield and possible toxic byproducts. 
In contrast, our cross-linking method involves only a single step of biomolecule 
attachment that occurs completely in aqueous solution. Moreover, we also showed that 
our modification method could be used in combination with the solvent casting-based 
patterning technique without loss of replication fidelity. 
 
4.2.3 Improving endothelial cell behavior using PVA with topography and attachment 
factor 
The ECM provides not only structural support for the attachment of cells, but also 
provides a combination of topographical and biochemical cues that appropriately directs 
cell behavior. PVA with topography, especially 10 µm gratings and microlens structures, 
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significantly improved HUVEC viability and proliferation in comparison to cells on 
unpatterned PVA. This is similar to studies in which micro or nano-sized gratings [8,79] 
and holes [8], fashioned after the in vivo basement membrane of endothelial cells [126], 
were shown to increase endothelial cell viability. We postulate that topography altered 
surface energy, hydrophobicity and consequently, collagen and fibronectin adsorption to 
PVA. A previous study performed on PLGA surfaces with nanospherical features 
exhibited an increasing trend of hydrophilicity with decreasing feature size [127]. They 
also found evidence for the dominance of vertical nanometer surface features and total 
surface area in affecting surface energy and hydrophilicity, compared to lateral features. 
Following this, topography on PVA may have decreased the surface hydrophilicity of the 
substrate, allowing some measure of protein adsorption compared to unpatterned PVA. 
In addition to increasing protein adsorption, topography may also be more amenable to 
conserve the active conformation of adsorbed serum proteins. The native conformation 
of fibronectin, either from serum or secreted by the cells, are better retained on surfaces 
with high curvatures such as microlens structures and grating edges [128]. For instance, 
nanosphere topography, similar to our convex microlens structures, was shown to retain 
the native conformation of adsorbed fibronectin [118]. Alternatively, topography by itself 
and independent of biochemical cues could have directly influenced cell behavior. 
Transduction of external mechanical force arising from cell-topography interaction into a 
cascade of cytosolic biochemical signals can alter gene expression and consequently, 
cell phenotype or even secretion of ECM proteins for adherence [129,130]. By mimicking 
the in vivo environment, our patterned PVA scaffolds could have stimulated the 
physiological gene expression regimen, leading to improved cell attachment, viability, 
proliferation and retention of function. This also explains the differences in the nuclear 
size detected between cells on patterned and unpatterned PVA (Figure 4.13). 
 
Despite the presence of topographical cues, overall cell attachment on PVA was not 
significantly enhanced. This led us to postulate that the hydrophilicity of PVA was still an 
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enormous impediment to cell adhesion and detection of the underlying topography 
[131,132]. Thus, we incorporated attachment factors into PVA to provide specific cell 
attachment cues for endothelial cells. PVA films modified with RGD-containing 
biomolecules (fibronectin, RGDS and cRGD) had modest effects on improving 
endothelial cell viability and adhesion. This was unexpected, as numerous research have 
shown the significant enhancement of endothelial cell adhesion on RGD-modified 
biomaterials [61,67,133]. Cross-linking of attachment factors was also expected to 
improve surface chemistry that would lead to cell adhesion: STMP-cross-linked PVA-
gelatin scaffolds had significant improvement in fibronectin adsorption and growth of 
immortalized endothelial cells [102]. Since our PVA scaffolds were modified in bulk and 
not confined to the surface, the amount of attachment factors exposed to the cells may 
have been inadequate to promote HUVEC attachment. Endothelial cells were found to 
be extremely sensitive to ligand density, requiring a minimum of 6 x 106 RGD 
ligands/mm2 for cell adhesion [134,135]. Alternatively, the random cross-linking of the 
attachment factors may have altered the active conformation or blocked critical serine, 
tyrosine or threonine residues. Further characterization of the modified PVA scaffolds, 
possibly using radio-iodinated peptides, atomic force microscopy (using integrin-coated 
or anti-RGD antibody-coated tips) or x-ray photoelectron spectroscopy may be 
necessary to evaluate the amount and distribution of the peptides immobilized [134]. 
 
Unexpectedly, heparin-PVA scaffolds did not have any desirable effect on endothelial 
cell behavior. Nilasaroya et al, who immobilized heparin to PVA using methacrylate, 
showed improved proliferation of BaF3 cells. The authors postulated that the specific 
binding of heparin to basic fibroblast growth factor (bFGF), an essential factor for BaF3 
growth, prevented rapid degradation and augmented growth factor presentation of bFGF 
[125]. VEGF, a heparin-binding growth factor that has mitogenic and chemotactic effect 
on endothelial cells, was also present in our HUVEC culture medium. Lack of endothelial 
cell proliferation suggests that the active sulfate and carboxylic side chains of heparin 
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may be sterically hindered inside the cross-linked network, thereby preventing heparin-
VEGF interaction [136,137]. This speculation should be verified with 
immunofluorescence staining using anti-heparin antibodies, measurement of absorbance 
shift with toluidine blue dye [138] or by applying a Factor X assay. We also observed the 
formation of micron-sized pits and a decrease in elasticity of heparin-PVA films. Though 
protein adsorption may have occurred, inadvertent topography on the surface may have 
rendered the relevant proteins inactive [131]. Moreover, the extreme loss of substrate 
stiffness of heparin-PVA hydrogel may have led to decreased HUVEC attachment, 
viability and proliferation. Heparin is a big molecule with the highest molar ratio of 
hydroxyl groups to PVA that could have easily interfered with cross-linking and changed 
the scaffold mechanical properties. Wood et al. observed the preference of HUVEC to 
grow on 50 kPa polyacrylamide substrates compared to a substrate with 25 kPa [139]. 
Thus, a change in the substrate stiffness of PVA may have had a deleterious effect on 
cell behavior. 
 
To further enhance the biofunctionality of PVA for vascular endothelial cells, we used 
both topographical and attachment factors to modify PVA films. Combining both 
biophysical and biochemical cues were hypothesized to better mimic the extracellular 
milieu of vascular endothelial cells. cRGD was chosen for its promising outcome in 
unpatterned PVA, well-documented hemocompatibility [70,71] and general positive effect 
on vascular endothelial cells [62]. Use of cRGD was intended to bind and activate αVß3 
integrins on endothelial cells to facilitate cell adhesion [140]. Integrins are a wide family 
of transmembrane proteins that mediate interactions between the cell and its 
microenvironment. Engagement of integrins activates various cell signaling pathways 
that induces a myriad of cell responses, including cell proliferation [120], migration [141] 
and differentiation [142]. The binding of ECM proteins or RGD peptides to integrins 
initiates a cascade of protein recruitment and biochemical signaling to create the focal 
adhesion [143]. One of these proteins, focal adhesion kinase (FAK), is recruited to the 
61  
 
focal adhesion, subsequently autophosphorylated and then acts as an effector protein for 
inducing the proper cell response. The phosphorylation site of FAK is important in 
determining its function. For example, the tyrosine-397 site is known for its function in 
mediating endothelial cell adhesion and spreading [144]. Therefore, we probed for 
phosphorylated FAK (pFAK) at tyrosine-397 to determine extent of endothelial cell 
attachment on patterned cRGD-PVA.   
 
pFAK in cells on unmodified PVA with topography were less structured and more diffuse, 
which suggests different signaling events other than the formation of focal adhesions 
[145]. Moreover, it implies the lack of complete cell adhesion, similar to what Sanborn et 
al. had observed in incompletely attached endothelial cells [146]. They also observed 
endothelial cells showing circumferentially-arranged actin fibers mainly at the periphery 
of the cell, denoting lack of integrin binding to the underlying substrate [120]. Lack of or 
incomplete integrin engagement and pFAK activation may induce apoptosis [147] and 
decreased endothelial cell proliferation [148], consistent with what we have observed. 
Meanwhile, the synergistic effect of both topographical and biochemical cues were 
observed, especially for PVA films with microlens structures. Cell adhesion on cRGD-
PVA was indicated by the formation of punctuate pFAK staining, reminiscent of focal 
adhesion structures on fully adhered endothelial cells [144,146]. Enhanced localization of 
pFAK in focal adhesions, in synergy with the effect of the topography, could 
consequently activate mitogenic signaling, accounting for significant improvement in cell 
viability on patterned cRGD-PVA compared to unpatterned and unmodified PVA. It may 
be necessary to examine the co-localization of pFAK with other focal adhesion proteins 
such as vinculin and paxillin to validate its function in HUVEC adhesion on PVA  
[149,150]. Nonetheless, based on the earlier reported results on PVA with a single 
modification, we expect the proliferation and function of HUVEC to be markedly 




The effect of topography on endothelial cells was most prominent on cRGD-PVA with 
gratings. Notably, some cells on cRGD-PVA with 10 µm gratings showed organized, 
parallel bundles of actin cytoskeleton. Furthermore, some cells on cRGD-PVA with 10 
µm or 2 µm gratings showed increased nuclear elongation and alignment to the grating 
axis. This was expected, as HUVEC was shown to be sensitive to gratings as small as 
400 nm in width [8]. Contact guidance was only observed on these cRGD-PVA films 
possibly because these films provided cRGD for initial cell attachment, which is a 
prerequisite to detect surface topography [130,144]. The alignment and elongation of 
cells along the gratings axis is imperative in recapitulating its phenotype in vivo, where 
alignment is induced along the direction of blood flow [151]. This fact has been shown to 
improve endothelial cell proliferation [8], migration [79] and repopulation of the scaffold to 
create a confluent monolayer. In addition, alignment of endothelial cells may act to 
contradict disturbed flow and shear stress [152], which is often seen in atherosclerotic 
states. A morphometric analysis of cell elongation and alignment should be performed to 
determine the effect of topography on cRGD-PVA substrates. 
 
The same phenomenon of improved pFAK signaling from focal adhesions may occur for 
endothelial cells on cRGD-PVA with microlens structures, which also showed improved 
cell proliferation and adhesion compared to its counterpart unmodified PVA. However, no 
specific orientation of cells was visible when they were grown on cRGD-PVA with 
microlens. We expected the cells to have arctuate morphology on microlens structures, 
similar to its morphology on randomly oriented, round topographies [153]. 
 
4.2.4 Hemocompatibility of PVA scaffolds with topography  
In addition to its effect on endothelial cells, we also demonstrated the improved 
hemocompatibility of patterned PVA substrates. As expected, platelets on patterned PVA 
substrates exhibited a less activated, rounded morphology and lacked aggregation. 
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Microparticle formation, which denotes activation and degranulation of platelets, 
surprisingly lacked significant differences between patterned and unpatterned PVA 
substrates. Studies have shown the effects of both ordered [87] and random [86] 
topography in retarding platelet activation as compared to flat substrates. Koh et al. has 
also demonstrated that the adsorption of fibrinogen and consequent activation of 
platelets were decreased on topographies in the sub-micron range [88]. It should be 
noted, however, that measurement of platelet activation in these references was 
significantly different from our methodology, which may obscure the comparisons 
between them.  
 
Nevertheless, it still remains that the blood compatibility of patterned and unpatterned 
PVA surfaces were identical. Undoubtedly, the surface hydrophilicity of PVA could 
influence blood compatibility more dominantly than topography via its effect on the 
complement cascade. Whereas hydrophilic surfaces prevent the adsorption of 
coagulation factors, the complement cascade may be activated by hydrophilic, negatively 
charged surface of PVA by binding to the C3b complement protein [53]. Platelet 
activation may occur afterwards via the interaction of the classical complement protein 
C1q with a hitherto unidentified platelet receptor [53]. This may explain why microparticle 
release from platelets on patterned PVA substrates did not differ from unpatterned PVA. 
It may be useful to further probe for the complement cascade response elicited by PVA 
to determine its full hemocompatibility profile.  
 
A similar study on STMP-cross-linked PVA-gelatin demonstrated its decreased 
thrombogenic potential as compared to unmodified PVA and glass substrates [102]. 
Likewise, we anticipate that PVA modified with cRGD, RGDS and heparin will show a 
decrease in microparticle formation and platelet activation whereas fibronectin-PVA will 
exhibit profound thrombogenicity. The combination of topography and cRGD on PVA 
should also decrease platelet activation by facilitating the rapid initial adsorption of 
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abundant serum proteins to prevent adsorption of coagulation factors [154]. An in vitro 
blood compatibility assay must additionally be performed to validate the 
hemocompatibility of these modified PVA scaffolds.  
 
 
The modification of PVA with topographical cues and attachment factors is a valid, 
feasible, and flexible strategy to improve its bioactivity. Incorporation of topography and 
cRGD ligand onto PVA scaffolds stimulated endothelial cell viability, adhesion and 





Results and Discussion – Controlled release of angiogenic factor 
from PVA small diameter vascular grafts 
The use of growth factors and biomolecules for the angiogenic treatment of PAD 
represents an alternative method for the revascularization of ischemic tissues. Various 
studies have shown that the controlled and sustained delivery of angiogenic growth 
factors is necessary for creation of stable neovessels and blood vessel collaterals. In this 
chapter, we examine the use of a composite scaffold of PVA with polyelectrolyte 
complexation (PEC) fibers for the controlled delivery of two angiogenic factors: VEGF 
and peptide VEGF mimic (QK peptide) conjugated to PEG. 
5.1 Results 
5.1.1 Fabrication of PVA tubular scaffold with PEC fibers 
PVA-PEC composite scaffolds (Figure 5.1) show good incorporation of the PEC fibers 
within the two layers of PVA. There was no apparent delamination of the three different 
layers, indicating good integration and individual integrity of the PEC fibers and PVA 
layers. Moreover, this implies that the incorporation of the PEC fibers did not interfere 
with the cross-linking of PVA.  
 
Figure 5.1. Incorporation of PEC fibers in PVA tubular scaffolds for 
controlled release of biologics. (A) PVA-PEC composite scaffold with fibers 
(red arrows) in between PVA layers. (B) PVA tubular scaffold made of 6 layers 
of PVA. 
!200 µm !200 µm A B 
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5.1.2 Controlled release of VEGF from PVA-PEC composite scaffolds 
To determine biomolecule release from PVA-PEC composite scaffolds, the therapeutic 
factor VEGF was used (Figure 5.2A). VEGF was encapsulated with an efficiency of 
96.22 ± 1.34%. Unexpectedly, only a cumulative release of 2.03 ± 0.07% VEGF was 
achieved for PVA-PEC scaffolds after 19 days. On the other hand, standalone PEC 
fibers (without PVA layers) achieved a maximum cumulative release of 23.40 ± 0.51% 
VEGF. Furthermore, VEGF release from the PVA-PEC composite scaffolds was 
negligible after 6 hours. Similarly, the plateau of VEGF release from standalone PEC 
fibers was realized in just 4 days after start of the controlled release. 
 
The bioactivity of released VEGF was also assessed (Figure 5.2B). The controlled 
release medium was found to have some effect on HUVEC proliferation, indicating some 
preservation of VEGF function. Moreover, there was no significant difference found 
between the effect of released VEGF from PVA-PEC composite scaffolds and 
standalone PEC fibers, which indicates same level of bioactivity despite difference in 
amount of release. As anticipated, HUVEC proliferation decreased starting at 171 hours, 
representing the plateau of VEGF release.   
 
Figure 5.2. Controlled release of VEGF (44kDa) from PEC fibers incorporated into PVA 
tubular scaffold and its effect on endothelial cell proliferation. PEC fibers were 
incorporated in a circumferential orientation. (A) Cumulative release profile of VEGF from 
PVA-PEC fiber composite tubular scaffold, compared to standalone PEC fibers. (B) 
Bioactivity of released VEGF as measured through an endothelial cell proliferation assay. 
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5.1.3 Controlled release of QK-PEG from PVA-PEC composite scaffolds 
Controlled release profile of VEGF (section 5.1.2) implied that PVA hindered the 
controlled release of VEGF from PVA-PEC composite scaffolds, which may be limited in 
the size of biomolecules that can diffuse through its cross-linked network. Preliminary 
experiments on QK-PEG (11.27 kDa) conjugates, a smaller angiogenic molecule, were 
performed. QK is a short peptide VEGF mimic that is engineered from the active helical 
motif of VEGF [155]. QK mimics the mitogenic, chemotactic and angiogenic properties of 
VEGF [97,98]. Santulli et al. has also demonstrated the in vivo capacity of QK to restore 
functional hindlimb vasculature similar to that of full length VEGF.  
 
Figure 5.3A shows the controlled release profile of QK-PEG. Encapsulation efficiency for 
QK-PEG was 95.77 ± 5.46%. A near-linear release of QK-PEG conjugates was observed 
for both PEC fibers and PVA-PEC composite after the initial burst release at 8 hours. 
Notably, the near-constant release profile was sustained for 14 days. The cumulative 
release for PEC fibers and PVA-PEC composites at each timepoint showed similarity, 
suggesting that the molecular weight and conformation of QK-PEG molecules 
represented the limit of diffusion through PVA hydrogel. 
 
Bioactivity of released QK-PEG was also assessed (Figure 5.3B). Released QK-PEG 
conjugates had a positive effect on HUVEC proliferation, signifying the functionality of 
QK-PEG. As expected from the near-constant release rate of QK-PEG, the bioactivity of 
QK-PEG was also consistent at all timepoints examined. No significant differences were 
found between the HUVEC proliferation induced by controlled release media from PEC 




Figure 5.3. Controlled release and bioactivity of QK-PEG (11kDa) from PEC fibers from 
PEC-PVA composite scaffolds. PEC fibers were incorporated in a bidirectional orientation. 
(A) Cumulative release profile of QK-PEG from PVA-PEC fiber composite tubular scaffold, 
compared to standalone PEC fibers. (B) Bioactivity of released QK-PEG as measured through 
an endothelial cell proliferation assay 
5.2 Discussion 
Therapeutic angiogenesis for the treatment of peripheral arterial disease and other 
occlusive diseases rely on the continuous delivery of a pharmacological agent. In this 
study, we used PEC fibers as a platform for biologics delivery. We incorporated PEC 
fibers into PVA tubular scaffolds to create small diameter vascular grafts that are also 
platforms for therapeutic angiogenesis.  
 
Controlled release from PEC fibers has been well established, allowing for spatial and 
temporal delivery of drugs, growth factors or cells [92,94,156]. However, its incorporation 
and utility as a growth factor delivery device in a composite vascular graft has not yet 
been studied. The controlled release profile of VEGF and QK-PEG was demonstrated in 
this study. VEGF showed a release profile with diminishing rate of release at increasing 
timepoints. This was unexpected, as the addition of heparin to the anionic polyelectrolyte 
solution was expected to regulate release. Liao et al. has previously demonstrated the 
near-constant release rate of platelet derived growth factor (PDGF) from PEC fibers 
using a similar combination of alginate and heparin [92]. The electrostatic interaction of 
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PDGF with the PEC fiber, which was postulated to play an important role in determining 
release kinetics, may not have been comparable to VEGF. The extremely large amount 
of VEGF loaded in the PEC fibers may have also hastened its release during washing 
[96]. It is also probable that VEGF released from both PEC fibers and composite 
scaffolds may have degraded during its release, despite the addition of BSA in the 
controlled release medium that maintains VEGF stability  [96]. This effect would be most 
evident at later timepoints, when intervals for release medium collection were further 
apart. In contrast, this effect was not reflected in the bioactivity of VEGF, where there 
were no significant differences observed between VEGF from PEC fibers or PVA-PEC 
composite scaffolds. It should be noted, however, that overall HUVEC proliferation 
stimulated by VEGF in the release medium was not robust. In contrast, PDGF released 
from PEC fibers were found to induce a 100% increase in cell proliferation of fibroblasts 
[92]. More sensitive techniques such as EdU assay for cell proliferation or western blot to 
detect VEGF receptor phosphorylation may need to be used to better measure minute 
differences in bioactivity of released VEGF. 
 
Nevertheless, it is obvious that the incorporation of PEC fibers in between PVA layers 
had a profound effect on the release of VEGF, but not on QK conjugates. Though their 
angiogenic and mitogenic properties were similar (Appendix B), their molecular weights 
are vastly different. VEGF is a dimer with a total molecular weight of 43 kDa, while QK 
conjugates are only 11 kDa. Their differences in molecular weight and even tertiary 
globular structure may have affected its diffusion through the non-porous PVA layers. 
This is true even for PVA hydrogel cross-linked with glutaraldehyde [157]. Matsuyama et 
al. observed that the diffusion coefficient of a molecule thru PVA films decreased with 
bigger molecules. Alternatively, though both are positively charged at neutral pH, VEGF 
may have a higher charge density owing to its longer peptide sequence. Increased 
charge density on each VEGF molecule could augment its electrostatic interaction with 
the monophosphate linkages of PVA.  
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Meanwhile, QK-PEG demonstrated near zero-rate release kinetics from both PEC 
standalone fibers and PVA-PEC composite fibers. Undoubtedly, the small molecular 
weight of QK had a profound effect on its release from PVA-PEC composite scaffolds, as 
seen from minimal difference in the total amount of peptide released from both scaffolds. 
Our results imply that the molecular weight of 11 kDa may be representative of the limit 
of diffusion through STMP-cross-linked PVA hydrogel. Significantly, the zero order 
release together with retained bioactivity implies delivery of a constant amount of 
angiogenic factor, which is imperative to stabilize new capillaries and arterioles [25,158-
160]. Moreover, the temporally and spatially controlled release of QK-PEG would prevent 
any aberrant, hitherto unknown effects of excessive growth factor concentration. 
 
Classically, angiogenic factors are introduced through the circulation through lifetime 
medication. Other methods for introducing growth factors for angiogenesis have involved 
microspheres [96,161,162], patches [50,163] or DNA vectors [99,164]. Recently, Han et 
al. showed the dual delivery of VEGF and PDGF from electrospun PEG-block-poly(L-
lactide-co-caprolactone) small diameter vascular grafts [12]. Despite the novelty and 
ingenuity of their vascular graft, they demonstrated very low encapsulation efficiencies 
and marginal release of both growth factors after 10 days. Moreover, their vascular graft 
lacked compliance, possibly contributing to the intimal hyperplasia observed after 
implantation in the rat carotid artery.  
 
On the other hand, our technique for growth factor delivery minimized losses, yielding 
very high encapsulation efficiencies. An additional advantage of using PEC fibers for 
growth factor encapsulation is the absence of any organic solvent and extensive post-
processing, thus preserving growth factor bioactivity. With this method, moreover, it is 
possible to encapsulate multiple biologics at a desired quantity for multiple release. For 
example, VEGF together with bFGF or PDGF, have been shown to synergistically 
improve angiogenesis in comparison to each factor administered alone [165,166]. By 
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adjusting polyelectrolyte composition and concentration for encapsulation, it may be 
possible to achieve both linear and sequential release of a therapeutic dose of any of 
these growth factors. In addition, heparin in the polyanion solution should prevent burst 
release of all these growth factors and improve presentation to its receptors [167]. This 
technique is not limited to growth factors but may also be used for cell and DNA delivery 
for therapeutic angiogenesis [93,95,168]. 
 
While the most important function of PEC fibers is the spatiotemporal control of biologics 
delivery, it must also be noted that the flexibility of manipulating PEC fibers allows control 
of its geometry, orientation and incorporation into any type of scaffold. Specifically, the 
process of PEC fiber formation allows molding of fibers while drawing from the PEC 
solution. With this method, we were able to incorporate PEC fibers onto PVA scaffolds 
with two different orientations. In both circumferential and bidirectional angular 
orientations, the PEC fibers did hinder cross-linking between the PVA layers thus 
creating an integrated scaffold. By changing orientation of the PEC fibers, mechanical 
properties of the PVA-PEC vascular grafts can also be more finely tuned. 
 
PVA-PEC fiber composite scaffolds represent a novel platform for the treatment of both 
macrovascular and microvascular occlusions. The use of PEC fibers for encapsulation 
and release of angiogenic growth factor enabled a near-linear release rate and functional 
preservation of the growth factor. These outcomes are beneficial for the development of 









Results and Discussion – Preliminary in vivo assessment of PVA 
in a peripheral artery disease small animal model 
 
PVA is an excellent material for vascular grafts because of its biocompatibility, non-
immunogenicity and non-antigenicity [42,169,170]. Moreover, its permeability to nutrients 
and metabolic waste [170,171] are useful for vascular tissue engineering. In chapter 4, 
we demonstrated the simple fabrication of unmodified PVA small diameter vascular 
grafts with sub-millimeter diameters. We also examined the mechanical and 
hemocompatibility properties of this vascular graft.  Finally, we further examined the 
feasibility of unmodified PVA small diameter vascular grafts for arterial replacement in a 
PAD small animal model.  
6.1 Characterization of PVA small diameter vascular grafts 
To better approximate the physical and mechanical properties of the rabbit femoral 
artery, PVA tubular scaffolds of 0.9 mm and 1 mm ID were fabricated (Figure 6.1A). The 
tubular scaffolds were shown to have uniform wall thickness (Figure 6.1B). Ultrastructure 
analysis via SEM revealed random roughness along the luminal surface of the PVA 
tubes. Mechanical properties of the PVA tubular scaffolds were also shown to 
approximate that of the rabbit femoral artery (Table 2). Notably, the compliance of the 
0.9 mm diameter PVA tubular scaffold was comparable to that of the rabbit femoral 
artery. Young’s moduli denote elasticity of both types of tubular scaffolds. The burst 
pressure, however, was found to be considerably lower than that of the rabbit femoral 
artery. Wall shear rate and wall shear stress in 1 mm ID PVA small diameter vascular 
graft were also calculated (Appendix A). Wall shear rate was calculated at 1409 s-1, 
which implies Newtonian behavior of blood, while wall shear stress was calculated as 




Figure 6.1. Uniformity of PVA small diameter vascular graft. (A) Sample PVA 
tubular scaffolds with 1 mm ID. (B) SEM images show cross sectional and longitudinal 
section of 1 mm and 0.9 mm ID PVA tubular scaffolds. Longitudinal section shows 




Table 3. Mechanical properties of PVA small diameter vascular grafts and reported 
values for rabbit femoral artery. * Denotes statistical significance between 1 mm diameter 
PVA graft and rabbit femoral artery. ^ Denotes statistical significance between 1 mm 
diameter PVA graft and 0.9 mm diameter PVA graft. 























































By easily varying the cross-linking conditions, type of tubular mold used and number of 
dip-casted layers of PVA, we were able to alter the mechanical properties of our PVA 
small diameter vascular grafts for our own application. It should be noted that the 
mechanical properties of STMP-cross-linked PVA graft (2 mm ID) were previously found 
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to approximate the mechanical properties of rat abdominal aorta [6]. We postulate that 
altering cross-linking parameters affects the microstructure of PVA by changing the 
amount of crystallite regions surrounded with amorphous region [172], which can be 
easily measured by x-ray diffraction or differential scanning calorimetry. 
 
Anisotropy of mechanical characteristics is an important characteristic of blood vessels, 
where greater strength in the radial direction is necessary for resisting failure from 
hydrostatic pressure. The apparent lack of radial strength, as shown by the low burst 
pressures, is a major limitation of our PVA small diameter vascular grafts. Nevertheless, 
it will be able to withstand the physiological peak in arterial pressures. PVA vascular 
grafts also had sufficient suture retention, which withstood enormous tension during its 
implantation in the femoral artery. Moreover, in comparison to other PVA-based hydrogel 
[44,173], our fabrication method did not compromise the strength and modulus of the 
vascular graft.  
Wall shear stress and wall shear rate are critical in determining response to a vascular 
graft. Too low shear stresses will stimulate intimal hyperplasia or even favor thrombus 
formation, while excessive shear stress may damage any endothelial cell that may attach 
to the luminal surface [40]. Together with caliber and compliance matching to the native 
femoral artery, wall shear stress inside PVA small diameter grafts differ only slightly from 
reported value of 5 Pa for rabbit femoral artery [176]. 
6.2 Blood compatibility of PVA small diameter vascular grafts 
The blood compatibility of PVA tubular scaffolds was also evaluated. Figure 6.2A shows 
the measurement of platelet activation using markers against GPIIb/IIIa (microparticles) 
and P-selectin. PVA small diameter vascular grafts slightly increased platelet 
microparticle release (4.25 ± 2.07%) compared to ePTFE (1.98±0.81%) and Silastic 
tubing (3.61 ± 2.22%), which is a bioinert material. In contrast, P-selectin expression of 
platelets on PVA (9.30 ± 3.135) was comparable to that of ePTFE (8.72 ± 6.71%) and 
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Silastic tubing (9.63 ± 6.11%). Surprisingly, microparticle release and P-selectin 
expression of platelets adhered on glass beads (2.91 ± 1.98, 1.77 ± 0.66%, respectively) 
were lower than that of the PVA tubular scaffolds. Morphologically, platelets on PVA 
tubular scaffolds were spherical, similar to the platelets found on ePTFE and silastic 
tubing (Figure 6.3B). Moreover, platelets were rarely and singularly found on the PVA 
scaffolds, whereas it was aggregated on ePTFE and silastic scaffolds. On the other 
hand, platelets on the glass bead surface were dendritic in morphology, denoting a 
highly activated state. Together, the microparticle expression and the rounded 
morphology of platelets that contacted PVA imply a semi-activated or refractory state.  
 
The hydrophilicity of PVA putatively prevents the adsorption of plasma proteins that 
activate platelet adhesion or blood coagulation [52]. In addition, the random roughness 
on the luminal surface of the PVA vascular grafts may be unfavorable for platelet 
activation [86]. However, lack of platelet adhesion does not preclude activation; in fact, 
platelets exhibited increased expression of P-selectin and GPIIb/IIIa receptor after 
contact with PVA. Platelets may have been activated through its intersection with an 
activated complement cascade [53], as previously discussed in section 4.2.4. 
Nonetheless, PVA was demonstrated to have an acceptable blood compatibility profile, 







Figure 6.2. Blood compatibility of PVA small diameter vascular graft. (A) Number of 
platelets expressing GPIIb/IIIa and P-selectin after contacting various surfaces. (B) 
Platelet morphology after attachment to various surfaces. Inset shows higher 
















































!2 µm !2 µm 




6.3 Patency of PVA small diameter vascular graft 
Laser Doppler flowmetry analysis of PAD animal model subjects with either femoral 
artery replacement using PVA vascular graft or permanent ligation (negative control) is 
shown in Figure 6.3. Prior to surgery, all animals had similar levels of surface perfusion 
percentage. A profound decline in surface perfusion percentage was observed 
immediately after temporary ligation of the femoral artery and embolization, denoted as 
Day 0. This is consistent with other studies using hindlimb ischemia models [96,177] as 
well as in patients with critical limb ischemia [178,179], thus verifying our PAD model. 
 
Negative control subjects exhibited a spike immediately after surgery and a subsequent 
drop in perfusion percentage. This may be attributed to the acute, yet inadequate, early 
response of collateral formation to hindlimb ischemia [180,181]. At the endpoint, the 
perfusion percentage in negative control subjects did not recover from the ligation and 
embolization, even when its endpoint was farther than subjects with PVA graft. Negative 
controls at day 25 and day 26 achieved 82% and 55% perfusion at the endpoint, in 
contrast to 95% and 102% basal perfusion, respectively, before ligation. It must be noted 
that negative control subject at day 15 exhibited an extremely high perfusion at day 12 
due to the application of a topical glucocorticoid (Panalog), which was used to treat a 
severe self-inflicted wounds and ulceration on the foot as a reaction to ischemia (Figure 
6.3A).  
 
On the other hand, subjects with patent PVA grafts demonstrated a slower increase in 
the percent perfusion immediately post-operation, in comparison to the negative control 
subjects. Nonetheless, the percent perfusion of subjects with patent PVA grafts reached 
the pre-operative, normal level after two weeks. Notably, the animal with 0.9 mm PVA 
graft reached percent perfusion of 101% at day 11 post-operation, while the basal level 
of perfusion was only at 69% prior to surgery. This indicated to us the possibility of both 
PVA graft patency and collateral formation in the PAD limb. A control subject without any 
79  
 
surgical manipulation exhibited a stable percent perfusion measurement across 30 days 
(Figure 6.3B), strongly implying that changes in percent perfusion were not inherent to 
the animal or the equipment used. 
 
 
Figure 6.3. Surface perfusion of PAD limb fully recovered in animals with 
PVA graft implantation. Graph shows numerical representation of laser Doppler 
values normalized to the normal limb (internal control). Images show graphical 
representation of data from laser Doppler imager. (A) Comparison of surface 
perfusion percentage between subjects that received PVA vascular graft and 
negative control. Inset: negative control rabbit with glucocorticoid treatment for foot 
ulceration. Day 0 denotes administration of embolic particles. (B) Surface perfusion 
of a limb in subject without PAD. 
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At approximately two weeks, angiography verified that 2 out of 3 subjects that received 
PVA grafts remained patent (Figure 6.4A). In contrast, negative control subjects all 
lacked patency of the left femoral artery, denoting total hindlimb ischemia [181]. 
Significantly, all 3 subjects that received PVA grafts (both patent and occluded) exhibited 
a higher number of collateral formation compared to the negative control hindlimbs. 
Quantitative analysis of the angiographs showed a similar trend, with higher number of 
pixels with blood flow for subjects with PVA grafts (Figure 6.4C). This correlated well with 
distal hindlimb perfusion through the saphenous artery (Figure 6.4B) and laser Doppler 
measurement of surface perfusion (Figure 6.3A), where subjects with PVA grafts 
retained blood flow through the saphenous artery regardless of conduit patency. 
Conversely, there was a lack of blood flow through the saphenous artery in all negative 
control subjects. This matches a study by Hershey et al, where revascularization of 
rabbit hindlimb ischemia started with sparse angiogenic collaterals at day 5 to day 10. A 
profound increase in thickness and number of collaterals were obvious only at day 20 
post-surgery [180]. This may also explain the fluctuations observed in laser Doppler 
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Figure 6.4. Patency of PVA small diameter vascular graft after 2 weeks. (A) Two 
PVA grafts implanted in the left femoral artery was patent after 15 and 17 days in a rabbit 
model of PAD. One PVA graft occluded 14 days after implantation. Negative control 
subjects lacked patency and exhibited vessel filling only through retrograde flow. Red 
arrow denotes patency while black arrow shows lack of patency. (B) Blood flow thru the 
left saphenous artery towards the left dorsal foot. Hindlimbs with PVA vascular grafts, 
regardless of patency, showed blood flow through the digital artery to left dorsal foot (red 
arrow). Negative control hindlimbs lacked blood flow to left dorsal foot. (C) Quantification 
of collateral formation using angiography videos. Amount of collateral formation is 
defined as number of vessels with blood flow (pixels) normalized to area of the hindlimb 
assessed (mm2). 
 
Explanted grafts with surrounding muscle were also sectioned and analyzed using 
histological techniques. Figure 6.5 shows both patent and occluded PVA grafts stained 
with H&E. Patent PVA grafts exhibited partial occlusion of the grafts with luminal tissue 
that was intensely stained with hematoxylin. Though its contour was similar to that of the 
graft, the tissue was not attached to the walls of the PVA graft. There are two possible 
sources for this tissue [182]: one, ingrowth of fibrous tissue or smooth muscle cells from 
the native artery, which could have invaginated into the PVA graft due to a diameter 
mismatch; two, the retention of large circulating blood cells - a less likely option given the 












































Figure 6.5. Morphology of explanted PVA small diameter vascular grafts. H&E 
staining of sections (20 µm thick) of both patent and occluded PVA grafts Top panel 
shows the whole graft surrounded by hindlimb muscle. Bottom panel shows higher 
magnification of luminal tissue.  
 
On the other hand, the occluded PVA graft had a blood clot filling the entire lumen of the 
graft. At such small calibers, impedance to blood flow is drastically magnified, leading to 
blood flow stasis, platelet activation and thrombosis [183]. The natural tapering of blood 
vessels compounded with large variation in the caliber of rabbit femoral arteries may 
have resulted in a profound mismatch in mechanical properties and, consequently, 
occlusion for this graft. 
 
The patent PVA graft was also examined for presence of endothelial cells in the luminal 
surface using an antibody against CD31 (Figure 6.6). The unimplanted PVA grafts 
served as a negative control to determine the amount of background staining from the 
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IHC technique. Unimplanted PVA grafts did not show any positive staining for CD31, 




Figure 6.6. Endothelialization of patent PVA small diameter 
graft. Patent PVA showed positive staining for CD31, compared to 
unimplanted PVA. Section thickness = 20 µm. Scale bars = 100 
µm. 
 
A positive signal for CD31 cells was unexpected, given the discouraging results of our in 
vitro examination on unpatterned PVA scaffolds (Chapter 4). Perhaps the random 
roughness of the PVA graft lumen, introduced by the tubular mold used for patterning 
(Figure 6.1), had some effect on protein adsorption. The network of protrusions 
(approximately 1 µm in width) may have increased adsorption of fibronectin from serum. 
The rounded edges of the protrusions would also improve in retaining fibronectin 
structure and function [118]. An alternative explanation would be the homing and capture 
of circulating EPCs. Activated platelets were shown to enhance interaction with EPCs 
and promote EPC adhesion and colonization in vitro [184]. Both the anastomosis site 
and the PVA surface (Figure 6.2) will initiate, to some extent, platelet activation that 
Unimplanted PVA Patent PVA D15 
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could consequently recruit EPCs to the implantation site. Moreover, this process may 
have augmented trans-anastomotic migration of endothelial cells, which was shown to 
reach only 1-2 mm beyond the anastomosis site after 2 weeks in a rabbit model [36,185]. 
Nonetheless, the presence of endothelial cells on the luminal surface of PVA vascular 
graft is highly desired and likely maintained the patency of the vascular graft for 2 weeks 
in the absence of anti-coagulants and anti-platelets. 
  
To wit, this is the first study that shows feasibility and patency of a small diameter 
vascular graft with sub-millimeter diameter in an animal model of PAD without the 
administration of any anti-platelet or anti-thrombotic post-operative regimen. This 
highlights two important findings about the PVA small diameter vascular graft: First, PVA 
small diameter vascular grafts have suitable characteristics to maintain short-term 
patency and facilitate anastomosis at sub-millimeter dimensions. Vessels at this 
dimension are technically challenging because of its fragility and susceptibility, including 
increased spasm and increased rate of thrombosis after clamping [186]. The matching of 
mechanical properties, especially the compliance, made the PVA graft easier to 
manipulate during suturing according to our surgeon. In addition, it may have improved 
the outcome of the anastomosis by minimizing manipulation of the native vessel. 
Spontaneous luminal opening of PVA graft coupled with its high modulus, suture 
retention and overall ease of handling also facilitated the anastomosis, thus reducing 
temporary ligation time to less than 3 hours, which may be considered the last reversible 
point of ischemic damage. Ligation of a major artery such as the femoral artery beyond 3 
hours will result in lack of muscle contraction and nerve stimulation, followed by atrophy 
and necrosis [187]. The excellent matching of the mechanical properties of PVA vascular 
grafts and the femoral artery likely minimized disruption of blood flow and allowed normal 
propagation of pulsatile flow. This may have also prevented any acute thrombotic or 
hyperplastic response that enabled endothelialization of the PVA vascular grafts.  
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Second, the implantation of a small diameter vascular graft in a rabbit PAD model has 
not yet been performed. Previous studies have shown patency of small diameter 
vascular grafts implanted in normal arteries: electrospun PCL graft (0.7 mm ID) in rat 
carotid artery [188]; electrospun PU graft (1.5 mm ID) in rat abdominal aorta [189]; PU-
heparin-PCL-collagen graft (2 mm ID) in beagle femoral artery [111]; RGD-PCL graft (2.2 
mm ID) in rabbit carotid artery model [9]. Most animal models used for assessment of 
vascular graft patency are insufficient to reproduce conditions of low and disturbed flow 
in an atherosclerotic vessel. Blood flow and shear stress were shown to have an effect 
on vascular graft healing and remodeling [190], endothelial cell behavior and function 
[191-193] and even blood compatibility and induction of blood coagulation [194,195]. 
Consequently, the use of normal animal models with healthy vessels for assessment of 
vascular graft patency may not convey results that will translate well clinically. The 
promising outcome of PVA vascular graft in an animal model of PAD encourages further 
exploration of this material for PAD treatment. 
 
A more robust experimental plan to validate efficacy of PVA small diameter vascular 
graft for treatment of PAD should involve commercially acceptable grafts of the same 
caliber. Unfortunately, we were not able to include either ePTFE or Dacron controls in 
this preliminary study because clinical-grade grafts with 1 mm or 0.9 mm ID are currently 
not available. Nevertheless, a few studies in the past decades showed that 1.2 mm ID 
Dacron vascular grafts implanted in a normal rabbit femoral artery have a 30% occlusion 
rate within 3 days, despite the administration of anticoagulant after implantation [196]. In 
addition, 1 mm ID ePTFE grafts implanted in the same model had 70% patency rate after 
15 days, but without any endothelial cells in the luminal layer [197]. Thus, we predict that 
when implanted in our PAD model, both ePTFE and Dacron will perform even more 
dismally than reported. Furthermore, we hypothesize that PVA small diameter vascular 
graft will be more effective, in both patency rate and collateral formation.  
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6.4 Histological assessment of collateral formation in rabbits with PVA small diameter 
vascular graft. !
In response to hypoxia and ischemia, angiogenesis is stimulated to ensure surrounding 
tissues have sufficient oxygen and nutrients. Angiogenesis is the sprouting of new 
capillaries from pre-existing capillary beds [19,198]. With consistent angiogenic factors in 
the vicinity, these capillaries may mature and stabilize to recruit pericytes and smooth 
muscle cells thus forming an small artery or arteriole with multiple layers of smooth 
muscle cells. Explanted grafts with surrounding muscle were assessed for capillaries or 
immature collaterals by detecting CD31 on endothelial cells. Meanwhile, arterioles or 
mature collaterals were detected by staining for α-SMA on smooth muscle cells. 
 
Explanted grafts with surrounding muscle were also assessed for collateral formation via 
IHC. Figure 6.7 shows muscle fibers positively stained with CD31 to demarcate 
capillaries. Capillary density was significantly higher in animals with PVA implantation, in 
comparison to negative control. In addition, mature collaterals that contained α-SMA 
fibers were significantly increased in animals that received the PVA grafts as compared 
to negative controls (Figure 6.8). The histological analysis of collateral formation 





Figure 6.7. Increased capillary density in animals with PVA graft implantation. 
Sections of hindlimb muscle surrounding the graft were stained for CD31 using IHC. (A) 
Representative images of muscles. Arrows show capillaries. Scale bar = 50 µm. (B) 
Quantification of capillary density.  
 
 
Both Figure 6.7 and 6.8 also showed differences in the quality of the muscle tissue from 
different animal subjects. Animals that received PVA graft implantation showed bundled 
muscle fibers with uniform size, implying that nutritive flow to muscles was not hindered 
by PVA. Meanwhile, negative control animals exhibited muscle fibers that had sharp 
corners and were spatially separated. This indicates the denervation and apoptosis of 
the muscle, which is characteristic of hindlimb ischemia models [97,99] and clinical PAD 
patients [199]. 
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Figure 6.8. Increased collateral density in animals with PVA graft implantation. 
Sections of hindlimb muscle surrounding the graft were stained for α-SMA using IHC. (A) 
Representative images stained. Arrows show blood vessels positive for α-SMA. Scale bar 
= 100 µm. (B) Quantification of collateral density. 
 
It was unexpected to observe a significant number of capillaries and arterioles formed in 
animals with PVA graft implantation, as compared to the negative control. The presence 
of mature collaterals implies that a constant angiogenic factor was present at the site of 
PVA graft implantation. In contrast, small collaterals formed in the negative control 
hindlimb indicate predominant formation of capillaries. Our results imply that the PVA 
graft, by itself, has an effect on the angiogenic response.  
 
We speculate that a slow narrowing of all PVA vascular grafts, regardless of the cause of 
narrowing or occlusion (Figure 6.5A), was occurring over time. The gradual onset of 
hypoxia, in contrast to immediate occlusion of flow in negative control subjects, could 
have induced a much faster angiogenic response. It has been shown that a hypoxic 
gradient is required in angiogenesis [200] to inhibit apoptosis and increase proliferation 
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the vessel wall during anastomosis or ligature, may also initiate collateral formation 
[202]. Active macrophages, together with the disruption of blood flow by platelets and 
rapid infiltration of immune cells, should provide a hypoxic signal to induce angiogenesis. 
Unquestionably, this process should occur for either set of animal subjects, but 
implantation of PVA may have augmented the inflammatory response at the 
anastomosis site. Our results, however, are not sufficient to verify this. Histological 
analysis of macrophage attachment or assays to determine the inflammatory response 
against PVA should be performed.  It may also be postulated that mechanical stimulation 
of the hindlimb in subjects receiving PVA vascular grafts induced a better angiogenic 
response [203-205] than that of negative control subjects, who were noticeably less 
mobile in the first three days post-operatively. Exercise-induced metabolic stress and 
mild-hypoxia may also stimulate an angiogenic response, as mediated by IL-6 and the 
inflammatory pathway [206]. It will be worthwhile to determine the cause of increased 
collateral formation in animals with PVA graft implantation.  
 
In this chapter, we demonstrated the feasibility of implanting PVA small diameter 
vascular grafts with sub-millimeter dimensions in a rabbit model of PAD. Notably, we 
observed the patency of PVA small diameter vascular grafts after 2 weeks of 
implantation despite the absence of anti-platelet or anti-coagulant therapy. Significantly, 
we showed presence of endothelial cells on the lumen that, together with the appropriate 
mechanical properties, facilitated short-term patency of PVA small diameter vascular 
grafts. The formation of an extensive collateral network in subjects with PVA graft 
implantation was unexpected, yet desirable for supplying blood to the distal 
microcirculation. Hence, PVA small diameter vascular grafts are excellent candidates for 






Synthetic small diameter vascular grafts are still lacking in long-term patency and 
efficacy, thus limiting its use for treating peripheral arterial disease. Significant limitations 
of small diameter vascular grafts are rapid development of thrombosis and intimal 
hyperplasia, arising from lack of spontaneous endothelialization and mechanical 
mismatching between the synthetic conduit and the native artery. In this study, we 
proposed to modify PVA for its potential application as a small diameter vascular graft. 
STMP-cross-linked PVA with tunable mechanical properties were modified with 
topography, attachment factors and controlled release of angiogenic factors to support 
endothelial cell adhesion, proliferation and function. 
 
We established a novel casting method for patterning of PVA hydrogel in both planar and 
tubular form. We showed that this patterning method could be adopted for both isotropic 
and anisotropic topographies of various geometries without any loss in fidelity or yield. 
We also demonstrated the flexibility and simplicity of modifying PVA with various 
attachment factors. In vitro studies showed that endothelial cells on planar PVA scaffolds 
with both topographical cues and attachment factors exhibited significantly increased 
attachment and proliferation. In particular, microlens structures on cRGD-PVA was the 
best for endothelial cell attachment and viability among all topographies studied. 
Meanwhile, gratings structures on cRGD-PVA guided endothelial cell attachment and 
morphology that may facilitate the formation of a physiologically relevant endothelium. 
Thus, incorporation of topographical cues and attachment factors in PVA scaffolds 




Controlled release of angiogenic factors from PVA small diameter vascular grafts was 
also performed. We created a composite scaffold by using polyelectrolyte complexation 
fibers embedded into PVA scaffolds. The PVA-PEC fiber composite scaffold served dual 
purpose as a vascular graft and reservoir for near-constant release of biochemical 
signals for therapeutic angiogenesis. Furthermore, angiogenic factors retained their 
capacity to stimulate endothelial cell proliferation after release from the composite 
scaffolds. Therefore, PVA-PEC fiber composite vascular grafts are an excellent platform 
for treatment of PAD through simultaneous replacement of a diseased artery and 
stimulation of collateral vessel growth. 
 
Finally, we examined the efficacy and patency of unmodified PVA small diameter 
vascular grafts in a novel PAD small animal model. In this proof-of-concept study, we 
showed that PVA vascular grafts with sub-millimeter dimensions remained patent for 2 
weeks. We showed endothelialization of the PVA grafts and extensive collateral 
formation in rabbit hindlimbs. The patency of PVA small diameter vascular graft, coupled 
with its capacity for endothelialization and collateral formation, makes this material 
potentially effective for PAD treatment. 
 
Overall, PVA has excellent potential for small diameter vascular graft application 
because of wide possibility and flexibility of modification and biofunctionalization, 
excellent mechanical properties for implantation and capacity to stimulate an extensive 
angiogenic response. This paves the way for a new and ideal small diameter vascular 








We demonstrated the successful modification of PVA with topographical cues and 
attachment factors. A better understanding of fundamental properties of the PVA 
hydrogel may be useful for a more systematic or controlled modification of the material. 
Techniques such as differential scanning calorimetry and thermogravimetric analysis 
should elucidate on polymerization kinetics, while X-ray diffraction may be used to 
assess crystallinity of PVA. By gaining a more fundamental understanding of the PVA 
hydrogel, more methodical approaches can be adopted to alter the chemical, physical 
and mechanical properties of the material. 
 
Topographical cues on PVA with attachment factor significantly improved cell viability 
and enhanced cell response to topography. Other topographies may be studied to 
determine its effect on endothelial cell behavior. Franco et al. [142] previously 
demonstrated improved endothelial cell spreading and contact guidance using gratings 
with smaller ridges and larger depths. It would be interesting to determine if this will hold 
true when applied to PVA. The feasibility of using these structures for tubular patterning 
must also be verified.  
 
The abundance in topographical cues available makes this task daunting. Measurement 
of interfacial properties, such as surface energy or contact angle, of patterned PVA 
scaffolds may be tested first to better predict topographies with the most significant 
impact on endothelial cell adhesion and function. On the other hand, a multi-
architechtural chip, which is an array comprised of multiple types of topography, may be 
used as an initial screening tool [150]. Either techniques may allow a more meticulous 
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approach in selecting the proper topography that can stimulate spontaneous 
endothelialization and recapitulate the confluent endothelial monolayer in vivo. 
 
Modification of PVA with cRGD was far from optimal; the ideal cRGD density must be 
achieved on the PVA surface. In addition, other attachment factors may be explored for 
modifying PVA. Aside from ECM proteins and its derivatives, antibodies against definitive 
markers have been used to capture specific cell types on to surfaces. For example, 
antibodies against E-selectin [119] and CD31 [207] have been successfully used for 
capture of endothelial cells.  
 
A critical determinant of the feasibility of patterned or modified PVA for vascular graft 
application would be its thrombogencity or hemocompatibility. Blood compatibility of both 
modified or patterned planar scaffolds and PVA small diameter vascular grafts may be 
better assessed by measuring lactate dehydrogenase secretion from activated platelets. 
Other assays, such as blood clotting time and thrombin generation time or ex vivo 
arteriovenous shunts, may be used to measure extent of blood coagulation. While effect 
of topography and surface attachment factors on platelet activation is well characterized, 
its effect on the complement cascade is not known. Thus, complement activation on 
different PVA modified surfaces should also be examined via a complement protein-
binding assay. 
 
We also showed a PVA-PEC fiber composite vascular graft that presents biochemical 
cues at a sustained and controlled manner for therapeutic angiogenesis. While sustained 
delivery of QK-PEG may prove to be effective in vitro, it may be worthwhile to test 
additional angiogenic factors such as bFGF and PDGF. The combination of multiple 
growth factors have been shown to initiate a faster and more stable angiogenic response 
compared to singular growth factor release [166]. In this case, it may be necessary to 
alter the cross-linking of PVA to result in near-linear release of growth factor without 
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compromising mechanical compliance. Mechanical testing of PVA-PEC composites must 
be performed to ensure that mechanical properties still match the native vessel to be 
replaced.  As appropriate, the PEC fiber spinning orientation or the component 
polyelectrolytes could be changed to obtain a more mechanically appropriate and 
biologically active composite vascular graft. 
 
The importance of matching mechanical properties must be emphasized, most specially 
for small diameter vascular grafts. Adopting the physiological mechanical properties of 
native arteries may result in better mechanical property matching. However, this may be 
challenging given that currently available data were obtained via explantation of the graft 
and testing in vitro. Weston et al. found that under sinusoidal flow conditions, mean 
shear stress across mismatched vessels are lower than when static flow is applied [56]. 
Hence, it is highly recommend to not only match the compliance and diameter or 
synthetic conduits and native artery, but to do it at the relevant physiological conditions. 
 
The final test of the value of the modifications (topography, attachment factors and 
angiogenic factor release) on PVA small diameter vascular graft is its implantation in a 
relevant PAD animal model. The efficacy, patency and extent of endothelialization must 
be assessed and compared with clinically relevant controls, such as ePTFE and Dacron. 
In addition, it would be interesting to determine the effect of several combinations of the 
modifications on endothelialization of the vascular graft and efficacy in treatment of PAD. 
However, this animal study should be performed in a larger animal model, where the 
appropriate caliber of clinical-grade ePTFE and Dacron grafts can be obtained 
commercially. Similar to what we have shown in this study, efficacy of the PVA vascular 
graft should be measured using clinically relevant techniques such as laser Doppler 
flowmetry. These results can be supplemented by measuring ankle-brachial blood 




We also showed the patency of PVA small diameter vascular grafts for two weeks in a 
small animal model of PAD. Long-term implantation of modified PVA should be done to 
determine not only patency and extent of angiogenic response, but also to examine 
immune reaction, vascular remodeling, biodegradation and changes in mechanical 
property of PVA in vivo. Prolonged implantation would also be useful to ascertain the 
cause of collateral formation. Collaterals arising from the wound-healing response are 
temporary and should regress after 2 weeks. On the other hand, true angiogenic 
response would stimulate a more permanent collateral network. 
 
It may also be useful to perform an in vivo subcutaneous test to determine the 
degradation rate of PVA hydrogel. This would be useful for predicting long-term 
response to the material, and to tune the mechanical properties or even the cross-linking 
method, as necessary. 
 
To become more clinically relevant, a longer PVA small diameter vascular graft should 
be implanted. Surgical replacement thru vascular bypass normally requires connecting 
the aorta or the iliac arteries to occluded arteries proximal to the knee joint. This requires 
vascular grafts with lengths at 10 cm or more. Longer segments of PVA grafts should be 
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Appendix A. Mechanical characterization of PVA tubular scaffolds 
Uniaxial tensile strength test 
Uniaxial tensile strength test (INSTRON 3345) was performed on PVA scaffolds. 
Samples were cut out to 2-3 cm. Excess water was dabbed off using a paper towel and 
each end was secured to the clamp with the help of paper tape. A final length of 1 cm of 
the scaffold (clamp end to clamp end) was used for longitudinal compliance testing. 
Testing was carried out at ambient conditions using a 10-N load cell under a cross-head 
speed of 10 mm/min. 3 samples were tested from each sample group. A representative 
stress-strain curve for PVA small diameter vascular graft (0.9 mm ID) is given in Figure 
A1.  
 
Figure A1. Representative stress-strain curve for PVA small diameter vascular 
graft. Slope of the initial linear portion of the graft was obtained to calculate the 
Young’s modulus. 
 
To obtain the Young’s modulus, the average cross-sectional area of each PVA tube type 
was correlated to the linear portion of the stress-strain curve for each sample. Cross-
sectional area was calculated from the inner diameter and wall thickness obtained (Table 
3). Cross sectional area, stress, strain and Young’s modulus are related by the equation 
 
This is an EXAMPLE TENSION test method.  This is a PROMPTED TEST where you are "prompted" step-by-step.
This example method is "Read-Only".
Make changes and choose "Save As" on the right.
Operator ID Harold
Company Super Duper Multi National Conglomerates R Us
Laboratory Name Central Laboratories
Rate 1 10.00000 mm/min
Humidity (%) 50.00000
Temperature (deg C) 18.00
Number of specimens in sample 10
                                                                              ABC Ltd.
                                                                          975 Fraser Drive
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Where  
E = Young’s modulus (N/m2) 
F= Force (N) 
A = cross-sectional area (m2) 
ΔL = change in length during stress application (m) 
L = original/gauge length (m) 
 
Radial compliance test 
Radial compliance test was performed to determine the effect of hydrostatic pressure on 
the diameter of PVA tubular scaffolds. A simple radial compliance test was adapted from 
Chaouat et al. [6]. Normal human diastolic and systolic pressure of 80 and 120 mmHg, 
respectively, were used for the compliance test. To approximate the hydrostatic 
pressures, two bags of water (1L) in were placed at different heights with respect to the 
PVA tubular scaffold. Intravenous tubing set was used to connect the bag of water to the 
PVA tubular scaffold, which was secured to a hypodermic needle. To prevent leaking of 
the PVA tube, the other end was sealed by a pair of mosquito (hemostatic) clamps. 
Images of the PVA tube under different hydrostatic pressures were taken using a Nikon 
SMZ745T stereomicroscope. Five samples were tested from each group. Compliance 
was calculated according to the formula  
 
! = !!!"# − !!!"!!" !!!100% 
 
Where  
C = compliance (%) 
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d120 = diameter of tube at 120 mmHg (mm) 
d80 = diameter of tube at 80 mmHg (mm)   
 
Burst pressure test 
Burst pressure testing was done to determine the maximum pressure that the PVA 
tubular scaffolds can withstand before failure. Similar to the radial compliance test, the 
PVA tubular scaffolds were secured to a hypodermic needle at one end and sealed with 
mosquito clamps on the other end. The hypodermic needle was connected to a nitrogen 
gas tank using tubing and a 3 ml syringe. The nitrogen gas tank was slowly opened to 
release gas into the PVA tube until failure. The pressure of nitrogen gas tank at failure 
was recorded as the burst pressure. Five samples were tested from each group. 
 
Suture retention test 
A single throw of 9/0 Prolene suture (Ethicon) was passed thru two opposite sites of the 
PVA graft. The suture was tied twice using standard surgeon’s knot. The graft was 
suspended at one end using a clamp, while the suture was attached to a modular 
container of known weight. Water was added gradually until suture rupture. The 
container was then weighed to obtain the total amount used for rupture (n=3). 
 
Calculation of wall shear stress and wall shear rate 
Wall shear rate [208] and wall shear stress [209] were calculated for 1 mm PVA small 
diameter vascular graft according to the following equations: 
! = ! ! + 2 !!!!  
! = !4!"!!!  
Where 
γ = wall shear rate 
Q = mean flow rate in femoral artery, 8.3 cm3/min [210] 
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r = radius of vascular graft 
m = constant that depends on flow condition. m=2 for laminar flow 
η = Newtonian blood viscosity, 3 x 10-3 Pa·s 
These calculations were made under the assumption of laminar and steady or non-
pulsatile flow, with a no-slip boundary condition. 
Appendix B. QK-PEG conjugation and bioactivity 
Conjugation of PEG-NHS and biotin-PEG-NHS was performed through standard 
succinimidyl ester conjugation methods. A method to specifically conjugate the NHS 
group to the N-terminus [211] of QK peptide was used, to avoid the inactivation of the 
lysine group on the peptide. In brief, QK and PEG, both in DMSO, were combined at a 
molar ratio of 1.5:1 in reaction buffer (50 mM phosphate, pH 6.5). After incubation at 4°C 
for 24 hours, the conjugated QK-PEG was then separated from unreacted QK peptide 
using size-exclusion centrifugation (Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-10 
membrane, 10 kDa molecular weight cut-off). Subsequently, the reaction buffer was 
replaced with PBS (pH 7.4) to reconstitute the QK conjugates. Conjugation of QK to 
PEG-NHS and biotin-PEG-NHS was performed separately. All QK conjugates were kept 
at -20°C until future use. 
 
To determine the bioactivity of the conjugated QK peptides, HUVEC proliferation assay 
and in vitro angiogenic assay were performed, as previously described (section 3.5.2 
and 3.3.5). 1 µM of QK, QK-PEG and biotin-QK-PEG was added to serum-reduced 
medium (EBM with 1% FBS, hydrocortisone, ascorbic acid and GA-1000). To compare 
the bioactivity of QK conjugates with VEGF, serum reduced medium with 1 pM human 
recombinant VEGF (Invitrogen) was also used. Serum reduced medium with PEG-NHS 
were included to examine any potential toxic effect of unconjugated PEG. Positive 
control of EGM-2 and negative control of EBM with GA-1000 were also included. 
Alamarblue assay was performed to determine cell proliferation at different timepoints. 
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Cell proliferation was calculated as a percentage of growth compared to basal 
proliferation (cells grown on serum reduced medium). Figure B1 shows the bioactivity of 
the different compounds tested. There is no significant difference between HUVEC 
proliferation when exposed to different compounds at Day 1 and Day 3. At day 5, the 
HUVEC proliferation for cells cultured in biotin-QK-PEG and QK-PEG were found to be 
significantly different from those exposed to QK, VEGF and PEG-NHS. These 
differences were more pronounced at day 7, when the bioactivity of cells exposed to 
VEGF and QK did not improve from day 5. Interestingly, the proliferation of cells exposed 
to PEG-NHS was consistent for 1 week, indicating that the compound may be inducing 
some basal mitogenic signal for endothelial cells. Moreover, the PEG moiety on 
conjugated QK peptides may aid in stimulating endothelial cell proliferation. This may 
explain how QK conjugates were able to surpass the level of HUVEC proliferation of QK 
and VEGF.  
 
 
Figure B1. Increased proliferation of HUVEC cultured with QK-PEG conjugates. 
































The Matrigel assay showed similar results. HUVEC (20000 cells/well) in different 
medium were incubated with 50 µl of Matrigel. QK-PEG conjugates retained the 
angiogenic capacity of HUVEC after 24 hours of culture in Matrigel (Figure B2). 
Interestingly, PEG-NHS was also able to improve tubular formation, in comparison to the 
basal serum reduced medium.  This reiterates our hypothesis that PEG-NHS by itself 
confers some mitogenic signal for endothelial cells.  
 
 
Figure B2. Retention of in vitro angiogenic capacity 
of HUVEC cultured with QK-PEG conjugates.  
Matrigel assay to determine tubular formation of HUVEC 
in serum reduced medium with various compounds. 
Images were taken 24 hours post-seeding. Scale bar – 
500 µm. !  
Biotin-QK-PEG QK-PEG 
QK 








Appendix C. PAD small animal model 
For eventual application of vascular grafts from the bench to the bedside, an appropriate 
animal model must be used for preliminary testing of the safety, feasibility and patency of 
the device [36,212]. Small animal models, such as rodents, for testing safety and 
feasibility of small diameter vascular grafts must be reproducible and have rapid 
occurrence of the biological event in question [36,212]. Many studies have shown 
feasibility of small diameter vascular graft implantation in rat, rabbit, dog, pig or sheep 
animal models with healthy arteries. For example, various small diameter vascular grafts 
have been implanted in the carotid artery [9,59,213] and abdominal aorta [41,73,74,214]. 
 
The main concern in using these preclinical models is the lack of similarity between the 
animal model and the pathological state in PAD and other atherosclerotic diseases. For 
instance, healthy animal models are insufficient to reproduce conditions of low and 
disturbed flow in an atherosclerotic vessel. Blood flow and shear stress are important 
determinants in vascular graft healing and remodeling [190], endothelial cell behavior 
and function [191-193] and even blood compatibility and induction of blood coagulation 
[194,195]. Consequently, the use of normal animal models with healthy vessels for 
assessment of vascular graft patency may not translate well clinically. Therefore, it is 
necessary to create a preclinical model that replicates the pathological state of PAD for 
the examination of small diameter vascular graft patency. However, there is also a lack 
of relevant models of PAD that are used preclinically. Hindlimb ischemia models, in both 
large and small animals, are predominantly used as a PAD model for the examination of 
therapeutic angiogenesis [215,216]. Nonetheless, hindlimb ischemia only incorporates 
disruption of the macrocirculation and is not a complete model of PAD. Therefore, in this 
study, we used a new animal model that had perturbation of both the macrocirculation 
and the microcirculation. By doing so, we were able to measure two physiological 
phenomena in a single animal model at the endpoint: collateral formation and the 
patency of the vascular graft. Both were estimated by the superficial blood flow to the 
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dorsal left foot (upper/front side of the left paw) and measured by laser Doppler 
flowmetry.  
 
First, ligation of the femoral artery during graft implantation served to induce temporary 
hindlimb ischemia. In negative control subjects, ligation of the femoral artery was 
permanent, mimicking a completely occluded vessel and total hindlimb ischemia [181]. 
Meanwhile, injection of microparticles was used to partially occlude the microcirculation 
of the left dorsal foot. Embolization of the left foot was effective, since surface perfusion 
significantly dropped immediately after this procedure (Figure C1). Since negative control 
subjects did not have any PVA graft implantation, the increase in surface perfusion after 
embolization can only be attributed to collateral formation. In contrast, improvement in 
surface perfusion in subjects with PVA grafts can be attributed to both blood flow through 
the PVA graft and collateral formation. The femoral artery runs distally to become the 
saphenous artery that mainly supplies blood for the foot. With this, we expected to 
observe more rapid improvement of surface perfusion percentage in subjects with PVA 
grafts.  
 
To assess changes in surface perfusion in response to the induction of PAD and graft 
implantation, laser Doppler flowmetry was used. Laser Doppler flowmetry has been used 
in measurement of ocular blood perfusion [217], cerebral blood flow after stroke [218], 
burn wound assessment [219], metabolic changes in skeletal muscle [220], and 
perfusion of rat anterior tibial muscle in a hindlimb ischemia model [221]. In contrast to 
laser Doppler imaging, which is widely used for assessment of recovery from hindlimb 
ischemia [177,222-224], laser Doppler flowmetry has not yet been established for this 







Figure C1. Correlation of laser Doppler flowmetry and imager for evaluating surface 
perfusion of PAD limb. Validation of method was performed on two animal models, (A) 
and (B). Top panel shows numerical representation of surface perfusion as measured by 
laser Doppler flowmeter and imager. Bottom panel shows images from laser Doppler 
imager. Day 0 denotes administration of embolic particles.  
 
Figure C1 shows percent perfusion values obtained using laser Doppler imager and the 
laser Doppler flowmeter for two test subjects with PAD induction and PVA graft 
implantation. Quantification of perfusion from laser Doppler images was done by taking 
the mean pixel intensity to a fixed area of a region of interest (ROI) and normalized to the 
ROI, which encompasses the tattooed spot on the dorsal foot. Meanwhile, readout for 
the laser Doppler flowmetry was taken after stabilization. Measurements were reported 
as a percentage of the surface perfusion of the left foot (PAD limb) to the right foot 
(normal limb). 
 
Absolute values of surface perfusion percentage varied between measurements made 
with the flowmeter and the imager at all timepoints. Nevertheless, there was a good 
correlation in the trend of measurements. The values measured by the flowmeter were 
also well represented by the laser Doppler images (bottom panel). Furthermore, 
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correlation analysis revealed no statistical significance between measurements obtained 
using imager and flowmeter (r2 = 0.034). We also used the laser Doppler flowmeter for 
estimation of vascular graft patency and collateral formation in the animal model. In 
contrast to the more commonly used and more visual laser Doppler imaging technique, 
the use of a laser Doppler flowmeter is more economical and flexible, allowing semi 
quantitative measurement of almost any surface of the body [225]. This may be sufficient 
for measurement of collateral formation, but validation of vascular graft patency must still 
be performed using angiography. 
Appendix D. Quantification of angiographic data using image analysis 
The quantification of angiographic data was adapted from Nowak-Sliwinska et al. [226]. 
Digital subtraction angiography videos were converted into its constituent frames using 
ffmpeg binary code for Mac [227]. Frames were then summed into a single 16-bit image 
using the Sum Stack function of ImageJ [228]. To avoid high background signals from 
the femur and tibial bones, regions of interest (ROI) anterior and posterior to the femur 
bone were drawn and retained using the ROI manager. ROI anterior to the femur was 
bounded by the femur, knee joint and the spinal column. ROI posterior to the femur was 
bounded by the femur, knee, tibia and the spinal column.  Afterwards, noise reduction 
and Gaussian filtering were applied to images. A posteriori shading correction [229] was 
applied, using automatic background correction. FFT bandpass filter was then applied to 
filter large structures to 90 pixels and filter small structures to 5 pixels. Afterwards, the 
image was then used for processing in two ways: First, for highlighting main vessels, the 
image was subsequently thresholded and despeckled to remove isolated pixels. Using 
the small region removal function [230], pixel clusters smaller than 200 pixels were 
removed from the image (Phase I image). Second, to obtain small vessels and 
capillaries, rolling background subtraction (200 pixels) and Gaussian filtering was applied 
to the image. The FeatureJ Laplacian function was then applied (smoothing scale = 2.0) 
and the image was subsequently converted to an 8-bit image. Finally the image was 
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thresholded and applied with the same small region removal protocol (Phase II image). 
Phase I and Phase II images were superimposed, and the ROI was placed back to 
calculate the number of pixels occupying blood vessels using the analyze particle 
function. Area of each ROI (in mm2) was also calculated to normalize pixel count. 
Collateral formation was reported as pixels per mm2. Representative images obtained 
during quantification process are found in Figure C1. 
 
 
Figure D1. Representative images from quantitative analysis of 
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